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Abstract 
Oral squamous cell carcinoma is commonly preceded by a range of cell and tissue alterations 
termed dysplasia, which indicate an increased risk of malignant transformation. Dysplasia is 
classified according to severity into mild, moderate, severe and carcinoma in situ. The early 
diagnosis, treatment and/or surveillance of these premalignant lesions are important factors in 
preventing progression to oral cancer. The current gold standard for screening and diagnosis of 
oral cancer and premalignant lesions is through histopathological diagnosis, which is limited 
by inter and intra observer and sampling errors. Although other methods are available for 
screening, most are not sensitive enough or do not provide enough information. Hence, there 
is a requirement for a sensitive, non-invasive method that can provide real time information. 
Raman spectroscopy fulfils these criteria, as it can provide detailed information on the 
biological content of a sample, through the unique vibrations of its constituent molecules. By 
analysing mild, moderate, and severely dysplastic formalin fixed paraffin preserved archival 
tissue samples; first within the same patient (intra-patient study), then between patients (inter-
patient study), it was found that Raman spectroscopy could classify mild, moderate and severe 
dysplasia in the same patient with an accuracy of over 90% in epithelium and over 80% in 
connective tissue. The findings of the inter-patient study were that the different degrees of 
dysplasia could be identified with an accuracy of 60%, while oral squamous cell carcinoma 
could be differentiated from dysplasia and benign lesions with an accuracy of 70% in 
epithelium and 80% in connective tissue. Confounding factors of the Raman classification of 
pathology, such as smoking and inflammation, were also evaluated. In addition, protocols for 
the processing of the Raman spectra of the oral tissues, including the subtraction of the wax 
and substrate were developed.  
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"Everything that living things do can be understood in terms of the jiggling 
and wiggling of atoms” 
 
-Richard Feynman, The Feynman Lectures on Physics, 1963 
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Chapter 1: Introduction  
1.1  Thesis Outline 
This study addresses the potential of Raman spectroscopy for applications in the diagnosis of 
dysplastic and malignant oral disease, based on tissue biopsies. Patients with benign oral 
lesions, mild, moderate and severe dysplasia and oral squamous cell carcinoma (OSCC) were 
consented during their check-ups at the Dysplasia Clinic of the Dublin Dental Hospital. The 
archival formalin fixed paraffin preserved (FFPP) samples from the patients with benign 
lesions, different levels of dysplasia and OSCC were collected from the Central Pathology 
Laboratory, St James’ Hospital, Dublin where all the oral biopsies are stored. The FFPP tissue 
sections were assessed with Raman spectroscopy.  
The broad objectives of the thesis were to; 
1) investigate the Raman profiles of an oral squamous cell carcinoma (OSCC) cell line at 
different phases of the cell cycle and to correlate these with biomarker expression in 
the different phases of the cell cycle  
2) optimise the processing of the Raman spectra from the FFPP tissue sections; which 
included removing the wax and glass background. 
3) discriminate between different degrees of dysplasia from the FFPP biopsies of 
individual patients with serial biopsies (intra-patient study). 
4) discriminate between benign, different degrees of dysplasia and OSCC from the FFPP 
tissues in a cohort of patients (inter-patient study). 
5)  evaluate the influence of patient factors and clinical features on the Raman spectra of 
the FFPP tissues 
Chapter 1 of the thesis is a general introduction to oral cancer, dysplasia and Raman 
spectroscopy. 
2 
 
Chapter 2 of the thesis is a review paper on the optical diagnosis of oral cancers, published in 
the journal, Head & Neck. 
The subsequent chapters address the aims/objectives of the thesis, chapters 3, 4, 5, 6 and 7 
addressing the objectives 1, 2, 3, 4 and 5, respectively.  
Chapter 8 presents a summary of the work, its clinical relevance and future perspectives. 
1.2  Oral Squamous cell carcinoma 
1.2.1  Overview/epidemiology 
Oral cancers are prevalent worldwide, having an estimated incidence of 300,400 new cases and 
145,400 deaths in 20121. Incidence is highest in South Central Asia, Eastern Europe and some 
regions of Oceania1. Oral squamous cell carcinoma (OSCC) is the predominant malignancy in 
most cases. It is more common in males than females, having a ratio of 1.5:1, and more 
common in older persons (aged 50 or over)2. Nevertheless, there are currently changes in the 
trend, manifest as an increase in incidence in young persons, which may be due to HPV 
infection as opposed to the traditional risk factors such as smoking and tobacco3. In Ireland, 
oral and pharyngeal cancers make up 3% of all cancers in males and 1.5% in females4. 
1.2.2  Carcinogenesis 
OSCC arises in the squamous epithelium and, like all cancers, is a multi-step process in which 
cells acquire mutations that allow them to evade immune surveillance and divide 
uncontrollably. Hanahan and Weinberg5 described six biological capabilities that enable 
tumour growth and metastasis which are; sustaining proliferative signalling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis. There are three main phases in carcinogenesis; 1) Initiation, 
in which one or more mutations arise in the cells either spontaneously or as a result of exposure 
to carcinogens, which increases the susceptibility of the cells for malignant transformation. 2) 
Promotion, which involves the clonal expansion of initiated cells, producing a larger population 
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of cells at risk for malignant transformation. 3) Progression, in which successive changes in 
the transformed cells give rise to increasingly malignant sub-populations6. 
1.2.3  Causes/risk factors 
1.2.3.1  Smoking 
Smoking is implicated in the development of a number of cancers including; lung, oesophageal, 
pharyngeal and oral cancer. It is responsible for 71% of oral cancers in developed countries 
and 37% in developing countries1. Over 60 carcinogens have been identified in cigarette 
smoke, including; benzene, vinyl chloride, tobacco specific nitrosamines and aromatic 
hydrocarbons such as benzopyrene, which has been linked to damage to the tumour suppressor 
gene P537,8 . Smoking, independent of other risk factors such as alcohol consumption, has been 
associated with a likelihood ratio of 2.15 of developing oral cancer9. The risk increases with 
increased consumption and is higher in females compared to male smokers10.  
1.2.3.2  Alcohol  
As with cigarette smoking, alcohol consumption has been linked to a number of cancers such 
as; oral, pharyngeal, oesophageal, and breast cancer11. It is estimated to be responsible for 3.5% 
of cancer deaths, although the mechanisms by which it causes cancer are poorly understood12. 
It is thought that acetaldehyde, the main metabolite of ethanol, may have a genotoxic effect. 
Moreover, alcohol is believed to act as a solvent for other carcinogens which would explain 
the synergistic relationship between smoking and alcohol consumption in the development of 
oral cancer11,13. The amount and duration of alcohol consumed has a direct effect on cancer 
risk and, in the oral cavity, the most frequently affected areas were found to be those most in 
contact with the alcohol, such as the tongue, oropharynx and larynx9,11. 
1.2.3.3  Smokeless tobacco and betel quid 
Smokeless tobacco is used in either chewing or snuff form and is sometimes combined with 
other substances such as betel quid. Similar to smoked tobacco, the carcinogenicity of 
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smokeless tobacco is attributed to tobacco specific nitrosamines, although their concentrations 
are different to the smoked form14. Smokeless tobacco has been associated with a relative risk 
of 2.6% of developing oral cancer15. Betel quid chewing is prevalent in Taiwan, India, Papua 
New Guinea, South-Africa and other Southeast Asian countries. However, it is not commonly 
consumed in Ireland.  Betel quid is prepared from the betel plant leaves and can be consumed 
with or without tobacco. The areca nut extract in betel quid has demonstrated mutagenicity and 
genotoxicity in animal models with areca alkaloids believed to be the major contributors16,17 . 
1.2.3.4  Human Papilloma Virus (HPV) 
The human papilloma virus (HPV) is generally associated with warts, epithelial cysts and 
benign neoplasias. However, two subtypes, 16 and 18, have been linked to cancer development. 
23% of oral squamous cell carcinomas (OSCC) were found to be positive for HPV and, of 
these, two thirds were positive for HPV-16 and a third was positive for HPV-1818. Remarkably, 
the survival of HPV positive cancer patients was higher than their HPV negative counterparts19. 
The carcinogenicity of HPV is due to the expression of E6 and E7; two viral oncoproteins 
which deregulate the cell cycle by interfering with the functions of PRB and P53, leading to 
cell immortalisation20. 
1.2.4  Anatomic site   
The anatomic site at which oral cancer develops has been found to relate to its aetiology, as 
cigarette smoking was associated with cancers in the retromolar area and floor of the mouth, 
while alcohol was most associated with floor of the mouth cancers. The buccal mucosa was 
associated with the lowest relative risk in both alcohol and cigarette smokers21. On the other 
hand, HPV was associated with cancers in the oropharynx and base of the tongue. Anatomic 
site is also linked to prognosis, base of the tongue cancers having the lowest five year survival 
(41.6%) and labial mucosa the highest (81.5%)22. This may be related to the fact that 
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carcinogens tend to pool at the base of the tongue and, moreover, the area is not easily visible, 
so the condition is usually advanced by the time it is diagnosed.  
1.2.5  Staging 
As with most cancers, oral cancer is staged according to the TNM staging system, which is an 
anatomical classification whereby; 
T: Extent (size) of primary tumour  
N: Regional lymph node involvement (absence or presence and extent) 
      M: Distant metastasis (absence or presence) 
 
 
Table 1-1 T staging based on the size of primary tumour23 
Tx Tumour could not be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ (CIS) 
T1 Tumour < 2cm 
T2 Tumour 2- 4 cm 
T3 Tumour > 4cm 
T4a Tumour has invaded local structures such as cortical bone, muscles of the 
tongue or skin of the face 
T4b Tumour has invaded into pterygoid plates, skull base or internal carotid artery 
 
Table 1-2 N staging based on regional lymph node involvement23 
Nx Lymph nodes cannot be assessed 
N0 Absence of regional metastasis 
N1 Involvement of a single ipsilateral lymph node, no more than 3cm. 
N2 Single ipsilateral lymph node more than 3cm in size, or multiple ipsilateral or 
contralateral lymph nodes, none more than 6cm 
N3 Involvement of lymph node more than 6cm in diameter 
 
 
 
6 
 
Table 1-3 M staging based on distant metastasis23 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
The TNM classification is used to determine cancer stage, which is important in making 
decisions in treatment choice and patient prognosis. 
Table 1-4 TNM classification23 
Stage T stage N stage M stage 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
 T1/2/3 N1 M0 
IV T4a N0 M0 
 T1/2/3 N2/3 M0 
 T1/2/3 N1/2/3 M1 
 
Another important classification is the histological grade, whereby the carcinoma is divided 
into 4 grades depending on the proportion of the tumour resembling the tissue of origin; 
Table 1-5 Histological classification24 
Grade I Well differentiated (<25% undifferentiated cells) 
Grade II Moderately differentiated (<50% undifferentiated cells) 
Grade III Poorly differentiated (<75% undifferentiated cells) 
Grade IV Anaplastic or pleomorphic (>75% undifferentiated cells) 
 
1.2.6  Oral Cancer Biomarkers 
A number of biomarkers have been considered for the assessment of oral cancer risk, 
progression, and survival. Epidermal growth factor receptor (EGFR) expression has been 
studied in oral cancer, as EGF is involved in many cell signalling pathways such as 
proliferation, apoptosis and angiogenesis25,26. EGFR has been associated with a higher risk 
(1.18%) of oral cancer development27, higher tumour grade28, and poor survival29. P53, a 
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tumour suppressor gene, is commonly expressed in a mutated form in oral cancers30,31. Its 
expression increases according to the degree of dysplasia in premalignant lesions32. However, 
no distinct association was found between P53 expression and oral cancer patient outcome or 
survival33,34. Cyclin D1 is a protein required for the progression of the cell cycle from G1 to S 
phase35. Overexpression of cyclin D1 has been linked to recurrence and reduced overall 
survival in oral cancer patients36,37. Thus far, none of the aforementioned biomolecules has 
been established in routine clinical tests for oral cancer. There may be a need for studies with 
greater statistical power before it can be determined whether any of these biomolecules could 
serve as biomarkers for oral cancer.  
1.2.7  Diagnosis 
Oral cancer can manifest as an endophitic (inward growth) or exophytic (outward growth) that 
can be a white or red patch or an area of ulceration. Some are symptomless, while others may 
be associated with bleeding, pain and/or soreness. In the more advanced stages, patients may 
present with symptoms like difficulty swallowing and swollen/tender lymph nodes in the 
neck38. Especially at the early stages, oral cancer may resemble other benign oral lesions. 
Therefore, after eliminating the possibility of other benign conditions, a suspicious lesion is 
biopsied by the dentist and sent for histopathological examination, which is the gold standard 
for oral cancer diagnosis. Other diagnostic aids include toluidine blue staining and brush 
biopsy, which are discussed in more detail in chapter 2. Early diagnosis is very important in 
oral cancer as stage at diagnosis is the most important prognostic factor39. After the initial 
diagnosis of OSCC is made, the stage of the tumour and presence of lymph node or distant 
metastasis is determined by the use of imaging techniques such as MRI, CT, and chest X rays40. 
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1.2.8  Management 
Oral cancers are treated with surgery, radiation therapy and chemotherapy, either as single 
modalities or in combination (multimodality). Several factors affect the choice of management 
in oral cancer patients;  
1. The extent of the disease; this depends on the TNM staging system as early small 
tumours are more amenable to radiation or surgery as a single modality therapy, while 
larger, more advanced tumours require more extensive surgical approaches and are 
more likely to have lymph node involvement. These are usually treated with 
multimodality therapy, in which surgery is coupled with pre or postoperative radiation 
and/or chemotherapy40-42.   
2. Patient factors; the age of the patient, compliance, and presence of comorbidities are all 
factors in determining the course of treatment in oral cancer41. 
Postoperative surveillance or follow up is crucial in oral cancer, as the tumour may recur or the 
patient can develop second primary tumours, which are tumours that develop in a different site 
in the oral cavity and are not metastasis from the primary tumour. Up to 30% of male and 20% 
of female patients develop second primary tumours2. The recommended follow up is every 2-
3 months in the first year, every 3-4 months in the second year, every 4 months in the third 
year, and every 5 months in the fourth year. Thereafter, a yearly follow up is recommended40. 
1.3  Potentially Malignant Oral Disorders and Dysplasia 
1.3.1  Potentially Malignant Oral Lesions 
Potentially malignant lesions are defined as; ‘a morphologically altered tissue in which cancer 
is more likely to occur than its apparently normal counterpart’43. The most commonly occurring 
potentially malignant lesion is leukoplakia, defined as; ‘a predominantly white lesion of the 
oral mucosa that cannot be characterized as any other definable lesion’43. Leukoplakias are 
further classified, according to clinical appearance, into homogenous and non-homogenous 
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lesions. Homogenous lesions are usually flat and thin and have a reduced risk of malignant 
transformation compared to non-homogenous lesions. Non homogenous lesions carry an 
increased risk of malignant transformation and include; speckled, nodular and verrucous 
leukoplakia. Erythroplakia is defined as ‘a fiery red patch that cannot be characterised clinically 
or pathologically as any other definable lesion’43. Erythroplakia may be smooth or nodular and 
has the highest potential for malignant transformation of any oral lesion43. 
1.3.2  Oral dysplasia 
While leukoplakia and erythroplakia are clinical terms which describe the appearance of the 
lesions, dysplasia is a histological term which describes the cell morphology and tissue 
architecture. Depending on the degree of cellular atypia and architectural changes, dysplasia is 
classified into mild, moderate, severe and Carcinoma in situ CIN. Dysplasia indicates an 
increased risk of malignant transformation and has been reported to occur in 5-25% of oral 
leukoplakias, while almost all erythroplakias show some degree of dysplasia44,45.   
1.3.3  Potentially Malignant Oral Conditions 
Potentially malignant oral conditions are described as; ‘A generalized state associated with a 
significantly increased risk of cancer’46. A number of these conditions exist, such as; Plummer- 
Vinson syndrome, oral submucous fibrosis, syphilis, xeroderma pigmentosum and discoid 
lupus erythematosus (DLE), all of which are associated with epithelial atrophy46.  
1.3.4  Progression 
It is hard to predict which potentially malignant oral lesions will progress to OSCC, but some 
factors have been associated with an increased risk, such as the presence of leukoplakia in non-
smokers and dysplastic changes47. However, histological grade is not necessarily an indicator; 
severe dysplasia may not progress, while mild dysplasia can progress to OSCC48. Intra-oral 
site and size of the lesion were not found to be significant predictive factors either49. Molecular 
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markers such as loss of hetrozigosity (LOH) on chromosomes 3p/9p, DNA content and P53 
expression levels have, however, shown promise in predicting OSCC development49. 
1.3.5  Diagnosis 
The diagnosis of potentially malignant oral disorders is similar to that for OSCC, as it starts by 
exclusion of other differential diagnosis, followed by a biopsy and histopathological 
examination. The problem with this system is that it is subjective and prone to inter and intra 
observer errors50. Additionally, a biopsy may not be representative of the whole lesion, and 
studies looking at the histology of tumours post operatively and comparing them to the pre-
operative biopsies have found that, in a significant number of cases, a neoplasia or carcinoma 
in-situ was misdiagnosed48. 
1.3.6  Management 
The current recommendation for management of oral premalignant lesions is that moderate and 
severely dysplastic oral lesions are removed either by surgery, laser or cryotherapy, while 
lesions with no or mild dysplasia are followed up every sixth month or third month 
respectively. Nonetheless, removal of the lesion was not found to significantly reduce the risk 
of OSCC development51. 
1.4  Raman Spectroscopy 
The current methods used in the diagnosis of oral premalignant and malignant lesions have 
their limitations. The standard method which is a conventional oral exam and histopathology 
is limited by intra and inter observer errors in addition to sampling errors48,50. Moreover 
dysplasia or OSCC may develop in an area of normal looking mucosa. Adjuncts such as oral 
brush biopsy and toluidine blue staining also have their limitations as they may produce false 
negative results and there is no information as to whether they can predict the probability of 
malignant transformation52. This demonstrates the need for new techniques for screening and 
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diagnosis. Optical diagnostics techniques, such as reflectance imaging, fluorescence imaging, 
and Raman spectroscopy are fast and non-invasive. They can have potential applications in the 
diagnosis of dysplasia and cancer which is discussed in more detail in chapter 2.  
1.4.1  Theory 
When electro-magnetic (EM) radiation interacts with a sample, it may be absorbed, or 
scattered. Most scattering is elastic, named Rayleigh scatter after the physicist who first 
described it, whereby the emitted (scattered) photon has the same energy as the incident photon. 
Mie scattering, named after the German physicist who first described it, is a similar process 
which dominates when the scatterers are larger than the wavelength of the light53. In 1928, the 
Indian physicist C.V Raman demonstrated experimentally that a small amount of the scattered 
radiation, about 1 in 1x106, is of a different energy than the incident photon, and the 
phenomenon came to be known as the Raman effect54. The Raman effect is the result of 
coupling of the molecular vibrational states with the photon, via the induced polarisation. If the 
sample molecules gain energy from the incident photon, the emitted photon has less energy 
than the incident one, as a result of the generation of a vibrational quantum. This effect is called 
Stokes Raman scattering. Conversely, if the molecule is in excited higher vibrational state it 
may lose energy to the emitted photon and go back to the ground state and the emitted photon 
would have more energy than the incident one. This effect is called anti- Stokes Raman 
scattering. Whether or not a molecule is Raman active depends on the polarisability of a 
sample, which determines the degree of scattering when exposed to EM radiation54. The Raman 
scattered light can be collected by a spectrometer and displayed as a Raman spectrum, in which 
the peaks (bands) correspond to Raman frequency shifts (measured in wavenumbers cm-1) 
caused by the characteristic vibrations in the molecules of a sample.  
The presence of an electric field E induces in the molecule an electric dipole µ given by; 
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𝜇 = 𝛼𝐸  
Equation 1-1 
where α is the polarisability, If the electric field is oscillating, which is the case for photons, 
the equation is given by; 
𝜇 = 𝛼𝐸0cos (2𝜋𝜈0𝑡) 
Equation 1-2 
where E0 is the electric field strength of the incident field, and ν0 is the frequency. An oscillating 
dipole will radiate electromagnetic energy at the frequency of oscillation. Polarisability is 
related to the degree to which electrons in a molecule can be displaced relative to the nucleus 
by the electromagnetic field of a photon. This displacement is described below. 
𝑞 = 𝑞0cos (2π𝜈𝑣𝑖𝑏𝑡) 
Equation 1-3 
where q0 is the amplitude of nuclear displacement and νvib is the frequency of the vibrational 
mode. If the nuclear displacement is small, then the polarisability can be approximated using 
the following equations. 
𝛼 = 𝛼0 + (
𝜕𝛼
𝜕𝛼
) 𝑞 
Equation 1-4 
where α0 is the polarisability of a molecule in its equilibrium position and (∂α /∂q) is the rate of 
change of α with respect to the change in q, evaluated at the equilibrium position. Combining 
Equation 1-3 and Equation 1-4 produces. 
𝛼 = 𝛼0 + (
𝜕𝛼
𝜕𝛼
) 𝑞0𝑐𝑜𝑠 (2𝜋𝜈𝑣𝑖𝑏𝑡) 
Equation 1-5 
Combining Equation 1-2 and Equation 1-5 results in. 
𝜇 = 𝛼0 𝐸0cos (2𝜋𝜈0𝑡) + (
𝜕𝛼
𝜕𝛼
) 𝑞0 𝐸0𝑐𝑜𝑠 (2𝜋𝜈0𝑡)𝑐𝑜𝑠 (2𝜋𝜈𝑣𝑖𝑏𝑡)  
Equation 1-6 
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This equation can be rearranged to describe three processes. 
µ = 𝛼0 𝐸0 cos(2𝜋𝜈0𝑡) + (
𝜕𝛼
𝜕𝑞
𝑞0 𝐸0
2
) {cos [ (2𝜋(𝜈0 − 𝜈𝑣𝑖𝑏)𝑡] + cos[2𝜋(𝜈0 + 𝜈𝑣𝑖𝑏)𝑡]} 
Equation 1-7 
The first term describes Rayleigh scattering, as the scattered photon has the same frequency as 
the incident photon (ν0). The second term describes Stokes scatter, as the difference between 
incident and scattered photon frequency is ν0-νvib, while the third term describes anti-Stokes 
scatter, as the difference between incident and scattered photon is ν0+νvib. The Boltzman 
distribution determines the relative intensities of Stokes and anti-Stokes scattering, which is 
dependent on the number of molecules in an excited state compared to those in the ground 
state. At room temperature, most of the molecules are in the ground state, and hence Stokes 
scattering is much more prevalent than anti-Stokes scattering.  
1.4.2  Instrumentation 
The different components of a Raman microspectrometer are shown in schematic form in 
Error! Reference source not found.. The source of the monochromatic incident light is a laser a
nd different laser wavelengths can be used, from ultra violet through visible to near infra-red, 
the choice of wavelength depending on the application. The interference filter is a clean-up 
filter which only allows the laser output through, while the neutral density filter determines the 
laser intensity, which is adjustable. For biological samples, coupling the Raman spectrometer 
to a microscope facilitates focusing on different regions of the cell or tissue. The objective lens 
both delivers the incident laser light and collects the backscattered (emitted) light. The 
holographic notch filter reflects the same wavelength as the incident light to remove all the 
Rayleigh scattered light and everything outside this range is considered Raman scatter and is 
transmitted. The grating is used to disperse the light and the groove density (measured in 
grooves/mm) determines the spectral resolution, higher groove density corresponding to higher 
resolution. Typically, gratings between 300 and 1800 grooves/mm are used. Other 
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determinants of spectral resolution include the wavelength, longer wavelengths having a higher 
spectral resolution, and the spectrometer length, which is the distance between the grating and 
the detector, longer distances providing higher resolution. Charge coupled device (CCD) 
detectors are commonly used with Raman spectroscopy as they are very sensitive to light. They 
also allow multichannel operation, so the entire Raman spectrum can be detected in a single 
acquisition. 
 
Figure 1.1 A schematic of a Raman microspectrometer based on the Horiba Jobin Yvon 
LabRAM HR 800* 
* Raman spectrometer model used in this study. 
1.4.3  Use in Diagnostics 
There has been a lot of interest in the use of Raman spectroscopy in medical diagnostics since 
its introduction to the field of diagnostics nearly 20 years ago55.  Its qualities, such as minimal 
sample preparation, speed, non-invasiveness, label free nature, and the fact that it gives both 
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qualitative and quantitative information on the molecular content of a sample make it 
particularly suited to such applications. Raman spectroscopy has shown promise in the field of 
microbiology by not only identifying the bacterial signatures but also response to antibiotics56. 
Furthermore, it has been studied for use in the diagnosis of coronary atherosclerosis and blood 
components57,58. Surface-enhanced Raman scattering (SERS) has been studied for use in 
detecting various biomolecules such as glucose, hemoglobins and RNAs59. It can also detect 
low levels of viral pathogens60.   
1.4.4  Use in Cancer Diagnosis 
The majority of the research on the diagnostic applications of Raman spectroscopy has been 
aimed at cancer diagnosis, either through in–vitro, ex-vivo (such as cytology, histology or the 
use of biofluids) or in-vivo techniques. Raman spectroscopy was successfully used to 
differentiate between normal and neoplastic lymphocytic cell lines mainly based on changes in 
DNA and protein profiles61. Ex-vivo studies have been carried out on breast histological 
samples and one study found that Raman Spectroscopy could discriminate between breast 
cancer and normal/benign conditions with a sensitivity and specificity of 94% and 96% 
respectively62. Similarly, Raman Spectroscopy has been used in cervical pathology to identify 
cancerous and precancerous stages63. Biofluids have a number of advantages which make them 
ideal for diagnostic tests as their collection is very simple, can be done repeatedly, and is non-
invasive. SERS on serum samples was used to identify prostate specific antigen (PSA) with 
diagnostic accuracy of up to 98%64,65. SERS on saliva samples could discriminate healthy from 
OSCC with an accuracy of 73%.66 A number of studies have looked into the in-vivo 
applications of Raman spectroscopy. Theoretically, Raman spectroscopy can be a very 
powerful diagnostic aid and could be used on mucosal and epithelial surfaces such as oral, 
cervical and skin by direct contact with the Raman probe and on the visceral surfaces by use 
with a needle or an endoscopic instrument. A study used Raman spectroscopy in the diagnosis 
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of skin cancers and discriminating different cancerous and benign lesions which yielded very 
high sensitivity but lower specificity67. Another study used Raman spectroscopy during 
gastrointestinal endoscopy by coupling the fiberoptic Raman probe with the endoscopic 
instrument, and compared normal to diseased states68. A good application for in-vivo Raman 
spectroscopy could be the examination of surgical margins during cancer surgery and one study 
has found promising results with margin assessment in breast cancer surgery69. However, these 
studies are hampered by small patient numbers which in turn reduces the ability of the 
classifiers, which are based on machine learning algorithms. Nevertheless, they demonstrate 
the possibility of Raman applications for in-vivo diagnostics. 
1.4.5  Use in Oral Cancer  
There has been a lot of interest in the use of Raman spectroscopy for the diagnosis of oral 
cancers, especially as the oral cavity is very accessible which facilitates ex-vivo and in-vivo 
Raman spectroscopic diagnosis. Inadequate resection margins in oral cancer surgery increase 
the likelihood of local recurrence70. The use of Raman spectroscopy as an aid in delineation of 
OSCC surgical margins has shown that OSCC can be discriminated from surrounding normal 
structures with a high degree of accuracy though it’s more likely to misclassify with 
surrounding normal and dysplastic epithelium71. Water concentration was found to be higher 
in tumours compared to normal tissue72. An in-vivo study study by Malik et al found that 
Raman spectroscopy can predict local recurrence in oral cancers with a sensitivity of 80% and 
specificity of 30%73.  
1.4.6  Use in Oral dysplasia and premalignant lesions 
There have been relatively few studies looking at the use of Raman spectroscopy for dysplastic 
oral lesions. One study that induced dysplasia in the palate of a rat model was able to distinguish 
between normal mucosa and low and high grade dysplasia with accuracies of 85 and 100% 
respectively74. Another study looking at surgical margins in sections of OSCC found that the 
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accuracy of the Raman classification for dysplastic tissue was only 48%71. Using OSCC and 
dysplastic cell lines and comparing them to normal cells, a study has found that Raman 
spectroscopy could discriminate between malignant, dysplastic and normal cells based on 
varying nucleic acid, protein and lipid profiles75. Interestingly, in all of these studies, the 
differences between malignant and normal were very noticeable, while the dysplastic changes 
seem to fall somewhere in between. Similar results have been reported from tissue studies 
which looked at normal, inflammatory or benign, premalignant and malignant oral lesions76-78.  
Overall these studies suggest that Raman spectroscopy can discriminate between normal 
mucosa and malignancy but in the case of oral dysplasia there have been no studies to show 
the effect of the different degrees on the classification of Raman spectroscopy. The use of 
Raman spectroscopy for oral premalignant and malignant lesion diagnosis is discussed in more 
detail in chapter 2, which is a review of optical techniques in oral cancer diagnosis. 
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Chapter 2: Recent advances in optical diagnosis of oral cancers: 
review and future perspectives 
 
Adapted from ‘Singh, S.P., Ibrahim, O., Byrne, H. J., Mikkonen, J. W., Koistinen, A. P., 
Kullaa, A. M., Lyng, F. M. (2015), Recent advances in optical diagnosis of oral cancers: 
Review and future perspectives. Head Neck. doi: 10.1002/hed.24293’ 
OI contributed figures and parts of the text. 
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diagnosis, oral cancer, oral dysplasia 
2.1  Abstract 
Optical diagnosis techniques offer several advantages over traditional approaches, including 
objectivity, speed and cost, and these label-free, non-invasive methods have the potential to 
change the future work-flow of cancer management. The oral cavity is particularly accessible 
and thus such methods may serve as alternate/adjunct tools to traditional methods. Recently, in 
vivo human clinical studies have been initiated with a view to clinical translation of such 
technologies. A comprehensive review of optical methods in oral cancer diagnosis is presented. 
Following an introduction to the epidemiology and aetiological factors associated with oral 
cancers currently employed diagnostic methods and their limitations are presented. A thorough 
review of fluorescence, infrared absorption and Raman spectroscopic methods in oral cancer 
diagnosis is presented. The applicability of minimally invasive methods based on serum and 
saliva is also discussed. The review concludes with a discussion on future demands and scope 
of developments from a clinical point of view.  
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2.2  Oral Cancers: An Overview  
Oral squamous cell carcinoma (OSCC) ranks as the 15th most common cancer in the world and 
10th most frequent in males. It accounts for ~2.1% of total cancer cases worldwide. Incidence 
rates are high among males in south central Asia and among females in eastern and central 
Europe1. Although mortality from oral cancer has decreased in the past few decades, it is still 
high and has a five year survival rate of 50%77. Several oral lesions and conditions are 
associated with an increased potential for malignant transformation. Of these, the most 
commonly occurring is leukoplakia, defined as ‘a predominantly white lesion of the oral 
mucosa that cannot be characterized as any other definable lesion’ Figure 2.1 (B). A wide range 
of malignant transformation rates have been reported, from 0.13-36.478%, depending on the 
presence and degree of dysplasia, location in the oral cavity and maturity of the lesion3,4. 
Conversely, erythroplakia, defined as ‘a fiery red patch which cannot be characterized 
clinically or pathologically as any other definable lesion’3, is less prevalent and has a higher 
potential for malignant transformation (14.379-66.780 %)5. Oral submucous fibrosis is a 
premalignant oral condition arising mostly due to areca nut or betel quid chewing6. It has a 
reported transformation rate of 7.6%6. Oral lichen planus is an inflammatory disease of the oral 
mucosa. Like leukoplakia, it presents as a white plaque or patch. However, its malignant 
transformation rate is much lower than leukoplakia, ~1%7 Figure 2.1 (C).  
A number of risk factors are associated with oral cancer, including cigarette smoking and 
alcohol consumption, which are responsible for 42% and 16% of oral cancer deaths 
respectively8. The carcinogenicity of cigarette smoke has long been established, resulting in 
DNA damage and increase in P53 mutations9. The association between alcohol and oral cancer 
was reported to be dose dependent and a number of factors may contribute to its 
carcinogenicity, including acetaldehyde, an alcohol metabolite thought to be carcinogenic10. 
Moreover, alcohol is thought to act as a solvent for other carcinogens10. Oral habits such as 
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smokeless tobacco and betel quid chewing are also implicated in oral cancer development11. 
They are more common in the Asian population; in India, 50% of oral cancers arise due to 
smokeless tobacco chewing11. The carcinogenicity of smokeless tobacco arises from the 
production of nitrosamines11. Oral squamous cell carcinoma has also been associated with the 
Epstein Bar (EBV) and Human Papilloma (HPV) Viruses, although their putative role is 
controversial. Around 23% of OSCC were found to be positive for high risk HPV 16 and 18 
12.  
 
Figure 2.1 Clinical presentation of (A), tongue cancer (B) leukoplakia and (C) lichen planus  
2.2.1  Current Screening/Diagnostic methods and limitations: 
Screening tests or diagnostic aids presently available for oral cancer include conventional oral 
examination (COE), staining with toluidine blue, oral brush biopsy and scalpel biopsy coupled 
with histology. 
2.2.2  Conventional Oral Examination (COE):  
Conventional oral examination (COE), using normal (incandescent) light, has long been the 
standard screening method for oral abnormalities. As it is a visual method, it cannot identify 
early mucosal abnormalities that may or may not lead to oral cancer. Approximately 5-15% of 
the general population has oral mucosal abnormalities and the vast majority of these lesions 
are benign in nature 13, Furthermore, only a small percentage of leukoplakias are progressive 
or become malignant and COE cannot discriminate between these and their non-progressive 
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counterparts. Therefore, while COE may be useful in discovering some oral lesions, its 
potential in identifying all potentially premalignant or biologically relevant lesions that are 
likely to progress to cancer is questionable.  
2.2.3  Toluidine blue staining 
Toluidine blue (TB), has been used for more than 40 years as an aid to detection of mucosal 
abnormalities of the cervix and the oral cavity. TB is a metachromatic, acidophilic dye that 
binds preferentially to tissues undergoing rapid cell division (inflammatory, regenerative and 
neoplastic tissue), resulting in preferential staining of abnormal tissue. Overall, TB appears to 
be useful in detecting carcinomas, but is positive in only ~50% of lesions with dysplasia. In 
addition, it frequently stains common, benign conditions such as non-specific ulcers. The high 
rate of false positive stains and the low specificity in staining dysplasia are some of the accepted 
limitations of the technique 14.  
2.2.4  Oral brush biopsy 
 Oral brush biopsy extracts a complete trans-epithelial biopsy specimen, with cellular 
representation from each of the three layers (basal, intermediate and superficial). Because the 
brush biopsy detects only cellular atypia, positive results must be confirmed with a scalpel 
biopsy for definitive diagnosis.  This technique has therefore been criticized for adding time 
and cost to the diagnosis of oral lesions without additional benefit to the patient15.  Overall, it 
is a method of identifying unsuspected oral cancers found during a visual examination, at early 
and curable stages16.  
2.2.5  Histology 
 Histological risk stratification, currently the gold standard for oral cancer diagnosis, requires 
biopsy, staining and microscopic examination by a pathologist17. However, removal of tissue 
or biopsy is an inherently invasive procedure and carries risk of complications in the proximity 
of vital anatomy. Sampling errors in collecting or interpreting biopsies due to inter-observer 
29 
 
discrepancy can be significant. Once removed, the tissue can undergo biochemical changes 
which can lead to artifacts. In many diseases, tissue involvement is not uniform, potentially 
leading to sampling errors. Especially in oral cancers, some early lesions are clinically 
indistinguishable from benign conditions. Furthermore, histologically, identification of subtle 
changes in precancerous lesions or in normal mucosa that are indicative of early neoplastic 
transformation is subjective and can lead to inter-observer variations 18. 
It is therefore conceivable that the primary prevention of the disease would involve activities 
to reduce or eliminate the use of tobacco and alcohol. Secondary prevention includes activities 
that are aimed to detect the disease at an early stage which would lead to better prognosis and 
lower morbidity. Current methods of detection of oral cancers are based largely on visual 
observations of abnormalities in tissue or cellular morphology and are therefore limited in 
terms of sensitivity and specificity, particularly at early stages. In the following section, a 
general discussion on the application of optical spectroscopic methods as an alternate/adjunct 
diagnostic tool for oral cancer is presented. 
2.3  Optical spectroscopy in oral cancer diagnosis 
Spectroscopy is the study of the frequency dependence of the interaction of electromagnetic 
radiation (light) with matter. Generally, light interacts with matter through absorption, emission 
and scattering/reflection. In each case, the spectrum of the interaction gives information about, 
and is characteristic of, the structure and chemical content of the sample. Optical measurements 
provide quantitative information based on the spectroscopic signature of the biochemical 
constituents of the sample that can be rapidly analyzed to yield an objective diagnosis, even in 
the hands of a non-expert operator. Diagnosis is based on biochemical changes underlying the 
pathology rather than visual or microscopic changes in cellular or tissue morphology. Devices 
to make these measurements have become inexpensive, robust, and portable, because of 
advances in computing, optical, fiber-optical, and semiconductor technology. Approaches 
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based on fluorescence, Fourier-transform infrared absorption and Raman scattering 
spectroscopy have shown potential for improved detection of oral cancers. A brief introduction 
of these techniques and their potential applications in oral cancer diagnosis is presented in the 
following sub-sections. Figure 2.2 provides a schematic illustration of their typical method of 
application.  
 
 
 
Figure 2.2 A schematic of the typical application of optical spectroscopic techniques for 
diagnostic applications.  
The light source is delivered via a probe or microscope (for in-vivo or ex vivo/in-vitro 
applications respectively) to the sample (cells, tissue or biofluid). Upon excitation by an 
appropriate source, molecules can either; go to an excited state and reemit light in the form of 
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fluorescence (UV/visible lamp), absorb the light to generate vibrations within the molecules 
(Infrared lamp), or, by interaction with the vibrational modes of the molecules in the cells; the 
light is Raman scattered (visible or near infrared laser). The emitted/transmitted/scattered light 
is then collected by the probe or microscope and passed to a detector. The operator can then 
perform analysis on the resulting spectra and, using a prepared classifier, the output can for 
example be a yes, no, or maybe for the presence of cancer.  The technique can be modified 
according to the application; in-vivo, ex-vivo (histological or cytological) or in vitro.  
2.3.1  Fluorescence spectroscopy  
When a molecule is illuminated at an excitation wavelength lying within the absorption 
spectrum of that molecule, it absorbs the energy and undergoes a transition from the ground 
state to an excited state. The molecule can then relax back from the excited state to the ground 
state by emission of light at specific emission wavelengths. In the UV/visible/Near infrared 
region of the spectrum (~200-1000nm), light emission takes the form of fluorescence (or 
occasionally phosphorescence). A fluorescence emission spectrum represents the fluorescence 
intensity measured over a range of emission wavelengths at a fixed excitation wavelength and 
can provide information relating to the molecular characteristics of the fluorophore, Figure 2.3.  
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Figure 2.3 Comparison of typical fluorescence spectrum (riboflavin) and typical Raman 
spectrum of tissue (both normalised) plotted on an energy scale. 
The intrinsic bandwidth of the fluorescence feature is very broad, compared to the Raman 
spectrum, which has a multitude of narrow bands which are shifted from the source wavelength 
of 785nm (~1.6eV). The energy shift of the Raman band is a measure of the vibrational energy 
and for comparison with infra-red spectroscopy is usually expressed in wavenumbers (1/cm). 
Note the energy scales for the two spectra are different. 
 
In the late 1970s, cancer diagnosis based on auto-fluorescence (also called natural, intrinsic or 
endogenous fluorescence) of naturally occurring fluorophores such as collagen, elastin, keratin 
and NADH was initiated 19. The presence of disease can lead to changes in blood concentration, 
nuclear size, collagen content or epithelial thickness, which can alter the concentration and 
characteristics of the fluorophores. In oral cancers, it was demonstrated that the epithelial layer 
shields the strongly fluorescing collagen layer leading to a low intensity of fluorescence in 
cancers20. An ex vivo study used hamster buccal pouch as an experimental model to identify 
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spectral markers associated with different stages of oral carcinogenesis 21. Onizawa et al., 
compared fluorescence spectra from human and hamster biopsies and oral cancer cell lines, 
suggesting that variation in the riboflavin and porphyrin fluorescence can be used as a 
spectroscopic marker for normal and cancerous conditions22. Ingrams et al. further showed that 
normal and cancerous human biopsies can be discriminated based on their autofluorescence 
spectral profile23. Another ex vivo study by Muller et al., explored the feasibility of quantifying 
the spectroscopic response of different grades of malignancy24.   
The first in vivo study using autofluorescence spectroscopy by Harris et al. reported differences 
between healthy and tumor mucosa based on the porphyrin emission band25. These differences 
were attributed to microorganisms living on ulcerating or necrotic surfaces. In vivo methods 
have also been explored to understand oral cancer progression in animal models26. Gillenwater 
et al. recorded in vivo autofluorescence from oral mucosa of 8 healthy volunteers and 15 
patients with premalignant or malignant lesions27. Decreased intensity in the blue spectral 
regions, and increased porphyrin fluorescence in the red were observed. Based on the ratio 
between these, a sensitivity of 82% and specificity of 100% were reported 27. Various other 
studies have provided further evidence in support of in vivo fluorescence spectroscopy for non-
invasive oral cancer diagnosis28-30. A recent study by Shaizu et al. showed that 
autofluorescence spectroscopy can be used to identify oral cavity disorders caused by long-
term tobacco habits. Their findings suggest that lower collagen levels and increased ratios of 
flavin adenine dinucleotide (FAD) to nicotinamide adenine dinucleotide (NADH) can serve as 
prognostic markers for oral cancer risk 31.  
However, tissue contains few natural fluorophores and their spectroscopic features are broad 
and overlapping, making them poorly distinguishable, reducing the specificity of fluorescence 
spectroscopy for diagnostic applications. 
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2.3.2  Fourier-transform infrared spectroscopy  
Vibrational Spectroscopy is a subset of spectroscopy which analyses vibrations within a 
molecule (or material). The vibrations are characteristic of the molecular structure and, in 
polyatomic molecules, give rise to a spectroscopic “fingerprint”. The spectrum of vibrational 
energies or frequencies (expressed as wavenumbers, cm-1) can thus be employed to characterise 
a molecular structure, or changes to it due to the local environment or external factors 
(radiation, chemical agents). Vibrational energies fall within the mid Infrared (IR) region of 
the electromagnetic spectrum and are commonly probed through IR absorption spectroscopy. 
High energy or frequency vibrations are characteristic of light, tightly bound groups such as C-
H, N-H and O-H, whereas low frequencies are associated with heavier groups, or collective 
vibrations such as ring breathing or skeletal stretches in macromolecules (Figure 2.4). 
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Figure 2.4 Comparison of typical IR absorption and Raman spectra of human tissue samples.  
The IR spectrum is in the mid infrared region of the spectrum, and the spectrum is less rich in 
information than the Raman spectrum. The Raman spectrum is expressed as wavenumber shift 
from the source laser line, although as shown in Figure 2.3, the scattered light is in the visible 
region of the spectrum. Both show typical features of lipids (●), proteins (▲), carbohydrates 
(■) and nucleic acids (♦). Note the strong absorption due to trace water in the FTIR spectrum 
in the region of ~3300cm-1. 
 
IR spectroscopy is now a routine technique for materials characterisation and has found 
numerous applications in forensics, environmental science and pharmacology32. Applications 
to tissue samples for (cancer) diagnostic applications were first reported in the early 90s, and 
since this time a range of pathologies has been investigated33. 
Wu et al. demonstrated that, on the basis of lipid and protein content, normal and tumor oral 
tissues can be discriminated34. In another study, of 10 normal sub-gingival tissues (NST) and 
15 oral squamous cell carcinoma (SCC) tissues, Fukuyama et al. demonstrated that the normal 
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spectra are strongly influenced by the presence of collagen. They also suggested that spectra 
are influenced by keratin, which exists in the ectodermal cells35. A study using FTIR 
spectroscopy to understand oral carcinogenesis in animal models have also been reported 36. 
FTIR imaging methods have also been explored to analyze different aspects of oral cancers. A 
study by Schultz et al., to assess changes in biochemistry of well and poorly differentiated 
oral/oropharyngeal SCC by infrared microspectroscopy, demonstrated that DNA and keratin 
can provide spectral markers to differentiate between normal and SCC biopsies37. Bruni et al., 
by generating three-dimensional IR chemical maps, demonstrated that proliferating and 
regressive states of head and neck tumours can be identified38. Towards high throughput, 
automated analysis, Pallua et al. demonstrated that good quality FTIR images can be obtained 
from formalin fixed paraffin embedded tissue microarray sections providing molecular level 
information as the basis for diagnosis39.  
Compared to fluorescence, FTIR provides a detailed fingerprint of the biochemical content of 
the sample. However, although FTIR has been used for the analysis of human tissues ex vivo, 
the application of this method for in vivo diagnosis is limited, due to the short penetration depth 
and the fact that water is highly absorptive in the mid-IR range. Conventional optical fibres 
have limited transparency in the IR region, and therefore, in vivo studies are less frequent than 
fluorescence or Raman fibre optical applications. New developments based on attenuated total 
reflection (ATR) elements might help in implementing in vivo applications. 
 
 
2.3.3  Raman spectroscopy 
Raman spectroscopy is a complementary technique to FTIR and has its origin in the discovery 
of the Raman effect in 1928, for which C.V. Raman was awarded the Nobel prize in 193040. 
Similar to IR spectroscopy, Raman entails the coupling of incident radiation with molecular 
vibrations and the resultant spectrum is similarly characteristic of the material. However, 
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whereas IR spectroscopy involves the absorption of radiation, Raman spectroscopy is a 
scattering technique, whereby the incident radiation couples with the vibrating polarisation of 
the molecule and thus generates or annihilates a vibration. The differing underlying 
mechanisms results in a complementarity of the techniques. Vibrations of asymmetric, polar 
bonds thus tend to be strong in IR spectra, whereas Raman is particularly suitable as a probe 
of symmetric, nonpolar groups. Notably, O-H vibrations of water are very strong in IR spectra, 
but are extremely weak in Raman spectra, rendering Raman a potentially more suitable 
technique for in vivo applications Figure 2.3. A further implication of the differing physical 
origins of the techniques is that, whereas IR monitors the absorption of IR radiation, Raman 
scattering can be employed in the UV, visible or near IR regions of the spectrum Figure 2.2. 
Raman scattering thus offers intrinsically higher spatial resolution for mapping or profiling in 
a confocal microscopy mode, the limit of spatial resolution being determined by the wavelength 
(<1µm for Raman, ~5-10 µm for IR). The application of Raman spectroscopy to biomolecules 
was first demonstrated as early as the 1960s and by the 1970s biomedical applications were 
explored41. Whole cell, tissue and in vivo studies carried out on a range of pathologies have 
demonstrated the potential for diagnostic applications42. 
Raman spectroscopic applications in oral cancer diagnostics started with the analysis of normal 
and dysplastic tissue in a rat model by Schut et al. (2000). Dysplasia in the palate was induced 
by topical application of the carcinogen 4-nitroquinoline 1-oxide and sensitivity and specificity 
of 100% were observed43. This was followed by a study of human oral cancer biopsies by 
Venkatakrishna et al, they recorded spectra of 49 biopsies and obtained an average 
classification efficiency of 88%44. In 2004, a study carried out by Krishna et al. demonstrated 
the applicability of formalin fixed oral tissues for optical pathology, revealing significant 
differences in the epithelial region of normal and malignant samples, arising from the protein 
composition, conformational/structural changes, and possible increase in protein content in 
38 
 
malignant epithelia45. In 2006, Malini et al. demonstrated the efficacy of Raman spectroscopic 
methods in discriminating normal, cancerous, precancerous and inflammatory conditions46. 
Lipid rich features in normal conditions and prominent protein features in tumors and other 
pathological conditions were observed. Classification between different groups using 
multivariate statistical methods produced 100% sensitivity and specificity46. Raman mapping 
of tissue sections further elucidated biochemical changes within different epithelial layers 
which are associated with disease onset47. A study by Sunder et al. demonstrated that oral 
carcinomas of different pathological grades can also be differentiated on the basis of the 
relative intensities of bands associated with lipids and proteins48.  
 In vivo Raman spectroscopy using fibreoptic probes for identifying site specific 
variations in the oral cavity was reported by Guze et al. in 2009, indicating that different oral 
sites can be discriminated on the basis of level of keratinization49. Bergholt et al., (2011), 
characterized the Raman spectroscopic profiles of different oral cavity regions (inner lip, 
attached gingiva, floor, dorsal tongue, ventral tongue, hard palate, soft palate, and buccal 
mucosa)50. Fitting of reference biochemicals (hydroxyapatite, keratin, collagen, DNA, and 
oleic acid) and partial least squares-discriminant analysis (PLS-DA) were employed to assess 
the inter-anatomical variability. The findings suggest that histological and morphological 
characteristics of different sites have a significant influence on the in vivo Raman spectra, and 
different sites can be classified with an overall sensitivity and specificity of 85%50 .  Singh et 
al. demonstrated that in vivo spectra can be acquired in clinically implementable timescales 
and demonstrated the feasibility of classification of normal and pathological conditions51. This 
was followed by another study exploring tobacco induced cancer field effects in the oral 
mucosa52.  Sahu et al. demonstrated that in vivo Raman spectroscopy methods can also be 
utilized to understand age-related changes in the oral mucosa53. These findings were further 
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verified by a recent study showing anatomical variability and feasibility of identifying 
pathological conditions with in vivo Raman spectroscopy 54. 
2.4  Minimally invasive methods in oral cancer diagnosis 
 Bio fluids such as blood, urine, lymph, and saliva can provide substantial information about 
human health and are being widely investigated for clinical diagnosis of various diseases 
including oral cancers. The attraction of these specimens lies in the fact that they can be used 
for mass screening, due to ease in collection, transport and low cost55. Studies have been carried 
out on physiochemical properties of saliva using surface enhanced laser desorption and 
ionization time of flight (SELDI-TOF) coupled with mass spectrometry (MS) and high 
performance liquid chromatography (HPLC) to identify proteomic and enzymatic markers 
associated with oral cancer56. Other techniques such as laser-induced fluorescence coupled 
with HPLC, and capillary electrophoresis coupled mass spectroscopy have been employed to 
characterise salivary metabolites in oral cancer patients57,58.  
Recently, optical methods based on Raman, infrared absorption, and fluorescence 
spectroscopies have also been exploited for such investigations.  For example, enhanced levels 
of porphyrin in blood have been used as a diagnostic marker for various cancers including oral 
cancers59,60. Yuvaraj et al. characterized different salivary metabolites associated with oral 
cancers by fluorescence spectroscopy61. FTIR spectroscopy has been applied to study sputum 
in order to diagnose oral cancers and discrimination between normal and cancerous samples 
was achieved on the basis of changes in the protein and glycoprotein structure within cells62. 
Surface-Enhanced Raman spectroscopy methods (SERS) have been used to differentiate 
between normal and oral cancer patients using spectra acquired from saliva63. A recent study 
by Elumalai et al. demonstrated that Raman spectroscopy of urine samples of healthy subjects 
and oral cancer patients can offer potential diagnostic information with a discrimination 
accuracy of 94%64. The analysis of exfoliated oral cells by optical methods also holds enormous 
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promise for early disease detection and diagnosis. Diem and co-workers have carried out 
multiple studies on spectral cytopathology of oral exfoliated cells65,66. Their findings are 
suggestive of the tremendous potential of spectroscopic methods in identifying minor changes 
associated with disease onset. Nevertheless, diagnosis based on biofluids suffers from 
limitations such as low analyte concentration, longer acquisition time, prone to experimental 
errors etc. Considerable efforts have been undertaken to develop standard protocols and 
sensitive instrumentation. Signal enhancements with the help of nano-particles or surface 
coating is an active area of research 67. Concentration of samples using centrifugal filtration 
devices has been shown to offer an alternative which allows measurement of the analytes in 
the native aqueous environment68. This also allows fractionation according to molecular weight 
of the constituent analytes, potentially allowing the targeting of molecular biomarkers of a 
disease. Appropriate modification of the instrumentation, especially automation for collection 
and analysis of body fluids is also an area which requires constant development. Efforts should 
also be undertaken for large scale trials and database development to overcome inter-laboratory 
and instrument variabilities 69.  
2.5  Summary and Outlook 
Although the oral cavity is easily accessible to inspection, oral cancer patients often present at 
an advanced stage when treatment is less successful, thereby leading to high morbidity and 
mortality. Early detection is the best way to ensure patient survival and quality of life. The 
current gold standard for clinical diagnosis of oral lesions is biopsy and subsequent 
histopathological confirmation. The process is invasive, time-consuming and prone to inter-
observer variability. An alternate method of diagnosis that can enable non-invasive diagnosis 
of the oral cavity in individuals with suspicious oral lesions is warranted.  
 
 
41 
 
It is now well recognized that techniques based on optical spectroscopy can play a very 
important role towards this end. Spectroscopic measurements of tissue biochemistry, with 
sensitivity and specificity to localize changes enhanced by imaging, represent a measure of 
health (or disease) unattainable in current practice, and can provide sensitivities for early stage 
detection of biochemical, rather than simply morphological, abnormalities. Table 1 lists the 
advantages and disadvantages of the current screening/diagnostic methods and optical 
spectroscopy methods. Among the spectroscopic techniques described, fluorescence is perhaps 
the most technologically accessible, as it is simply based on the analysis of light which is 
emitted after illumination with a UV lamp. The emitted light is in the visible range and 
therefore probes can use free space or low grade, inexpensive fibre optics. The technique 
detects only the small fraction of endogenous biomolecules which are fluorescent, however, 
and relies on identifying pathology specific biomarkers amongst them. FTIR spectroscopy, on 
the other hand, produces a label free fingerprint of the complete biochemical content of the 
tissue, cell or biofluid, and this can explore more global and specific pathological changes. 
However, water is an extremely strong FTIR absorber, and so in vivo diagnostic applications 
may be limited. Raman spectroscopy provides a similar complete, label free fingerprint of the 
sample, and also couples to benefits of working in the visible region of the spectrum. Water is 
a weak Raman scatterer, and so the technique is more adaptable to routine in vivo patient 
screening or ex vivo spectral histology or cytology. The prospect is therefore of a high 
sensitivity and specificity, automatable, objective quantitative label free probe of early stage 
disease development and progression, based on the biomolecular content of the patient sample.  
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Table 2-1 Advantages and disadvantages of current screening / diagnostic methods and optical 
spectroscopy methods 
Technique Advantages Disadvantages 
Conventional 
oral 
examination  
Well accepted screening method 
No instrumentation or reagents 
required 
Rapid 
Subjective 
Requires clinical expertise and 
experience 
Unable to identify potentially pre-
malignant lesions 
Toluidine 
Blue staining 
No instrumentation required 
Rapid 
Subjective 
Requires clinical expertise and 
experience 
Reagents required 
Low specificity for dysplasia 
Oral brush 
biopsy 
Less invasive method for trans-
epithelial biopsy 
Rapid 
Subjective 
Requires clinical expertise and 
experience 
Reagents and instrumentation 
required 
Must be confirmed with scalpel 
biopsy and histology 
Histology Well accepted gold standard method 
Definitive diagnosis of tumour stage 
Stromal invasion can be determined 
Tumour margins can be determined 
Subjective 
Requires clinical expertise and 
experience 
Pre-malignant lesions difficult to 
distinguish from benign conditions 
Reagents and instrumentation 
required 
Invasive 
Inter-observer variations 
Sampling errors 
Slow 
Fluorescence 
spectroscopy 
Objective 
Can be used by non-specialists with 
suitable diagnostic algorithms 
No reagents required as based on 
intrinsic fluorescence of 
fluorophores such as collagen, 
elastin, keratin and NADH 
Can be used ex vivo or in vivo 
Can be used for cells, tissues and 
biofluids 
Instrumentation required 
Low specificity due to relatively 
few natural fluorophores with 
broad, overlapping features 
Infra Red 
spectroscopy 
Objective 
Can be used by non-specialists with 
suitable diagnostic algorithms 
No reagents required as based on a 
fingerprint of the biochemical 
composition 
Instrumentation required 
Limited use in vivo due to short 
penetration depth and interference 
from water 
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Mainly used ex vivo but in vivo may 
be possible using ATR-FTIR 
spectroscopy 
Can be used for cells, tissues and 
biofluids 
Short spectral acquisition times  
Low spatial resolution but can be 
improved with ATR-FTIR 
spectroscopy 
Multivariate data analysis needed 
to extract information from the 
spectral data 
Raman 
spectroscopy 
Objective 
Can be used by non-specialists with 
suitable diagnostic algorithms 
No reagents required as based on a 
fingerprint of the biochemical 
composition 
Can be used ex vivo or in vivo 
Can be used for cells, tissues and 
biofluids 
High spatial resolution allowing 
subcelluar imaging 
Increased penetration depth using 
SORS 
Instrumentation required 
Long spectral acquisition times 
Multivariate data analysis needed 
to extract information from the 
spectral data 
 
Variable thickness and degree of keratinisation at different sites in the oral cavity can 
influence the diagnostic efficacy of optical methods, especially for early lesions. This issue has 
been addressed extensively by the biomedical spectroscopic community. Various studies have 
successfully demonstrated the potential of spectroscopic methods in identifying anatomical 
variability due to different levels of keratinization. For example, a study by Rupananda et al. 
showed a higher fluorescence due to porphyrins in the tongue compared to other oral sites 29, 
while Guze et al found that Raman spectra can be clustered according to sites in the oral cavity 
49. Similar findings were reported by Bergholt et al.,  who found that the sites clustered into three 
groups; (1) buccal, inner lip, and soft palate; (2) dorsal, ventral tongue, and floor; (3) gingiva and 
hard palate 50. These studies have provided evidence in support of inherent differences between 
different locations and suggested that each site be treated independently. For example, spectral 
models developed using spectra from buccal mucosa cancers cannot be used for identifying 
abnormalities at tongue or palate. Most of the recent studies have been performed under these 
guidelines, where tumours of specific sites are treated separately51-54. As with all optical 
techniques, the depth sensitivity is limited by the absorption and scattering of the tissue. 
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Operation in the near infrared can optimise the depth sensitivity of Raman probes, and novel 
methodologies such as spatially offset Raman spectroscopy (SORS) promise increased 
penetration depths of several millimetres for deeper set lesions 70. Such technological advances 
potentially place Raman ahead of the field as candidate for in vivo optical diagnostic 
applications. 
In the coming years, large scale clinical trials must be conducted to gain the amount of 
site-specific data necessary for developing adequate size training and test sets for robust 
algorithm development and analysis. The standard models for each of the individual sites in 
the oral cavity should be tested rigorously, preferably double-blinded, as multi-centric studies, 
before they are considered for routine use. Several technological advances in terms of 
fiberoptic probes and miniaturization of instruments are also required for real time and routine 
diagnosis. Efficient suppression of background signal, optimization of collection optics, and 
incorporation of miniaturized interference filters in the fiber probes are some of the issues that 
are to be addressed effectively. Further improvements in data analysis algorithms are also 
required for developing less cumbersome, rapid, unambiguous, objective and user friendly 
interfaces from the point of view of routine clinical use where a clinician or a technician can 
analyze a given spectrum against all available models to diagnose a case. The prospective 
adaptation of optical spectroscopy methods for routine clinical diagnosis would decrease the 
number of follow-up clinic visits and patient anxiety by minimizing waiting times for 
histopathological diagnosis. The technology poses no known risks to the patients, and therefore 
could be a safe alternative/adjunct to the current diagnostic methods. 
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Chapter 3: Use of Raman Spectroscopy for the Study of Cell Cycle 
Phase and Biomarker Expression Levels in Oral Squamous Cell 
Carcinoma Cells 
 
3.1  Introduction 
 
The cell cycle is a highly regulated process with defined phases. G1 is the phase after the 
previous cell division during which the cell grows. The S phase is the DNA synthesis phase, in 
which the cell replicates its genetic material. In the G2 phase, transcription and translation are 
co ordinated to prepare for Mitosis (M phase). The cell cycle is associated with checkpoints in 
which the cell assesses its environment to ensure the conditions are appropriate for cell cycle 
progression. There are two checkpoints, one at the G1/S boundary and another at the G2/M 
boundary. Deregulation of the cell cycle can result in tumourogenesis1 and is often signalled 
by the overexpression of certain biomarkers, as, for example cyclin D1. Cyclin D1is one of a 
family of D type cyclins which also include D2 and D3. It is important for the G1 to S phase 
transition as it binds with the cyclin dependent kinases 4 and 6 to form an active complex that 
phosphorylates and inactivates retinoblastoma protein (RB) promoting cell cycle progression2. 
The overexpression of cyclin D1 leads to faster progression from G1 to S phase, which in turn 
results in increased proliferation and an increased propensity for the development of mutations. 
Cyclin D1 is overexpressed in a number of carcinomas such as breast, oesophageal, ovarian, 
hepatocellular, colorectal, and head and neck carcinoma3-8. Another biomarker, Proliferating 
cell nuclear antigen (PCNA), required for DNA replication, is synthesised in the late G1 and S 
phases of the cell cycle9. It acts as a polymerase clamp as well as a sliding platform for the 
recruitment of other replication proteins such as DNA helicase, ligase, nuclease, and histone 
chaperones10. Levels of PCNA have been found to correlate with increased dysplasia in oral 
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epithelial cells11,12. A thorough understanding of cell cycle dynamics is important for cancer 
research and tumour targeting. The ability to monitor the altered expression of biomarkers 
could prove valuable in cancer screening. 
Flow cytometry has been widely used in the study of cell cycle dynamics, as Propidium iodide 
(PI) is commonly used to quantify the DNA content which is characteristic of the cell cycle 
phase. Quantitative image analysis which utilizes fluorescent dyes has also been used to 
identify certain biomarkers that vary throughout the cell cycle13. Both these techniques rely on 
prior knowledge of the biomarkers to be studied and can only give information on a few 
biomarkers at a time. 
Using inhibitors to arrest the cell cycle at the various phases, previous studies have examined 
the use of Raman spectroscopy in the discrimination of the cell cycle phases. Using a prostate 
cancer cell line, and fixing the cells at the different cell cycle phases, one study found the 
greatest differences between the G2M and G1 phases and slight differences between the G1 
and S phases14. Similar findings were made by another study looking at live human 
osteosarcoma cells, although, unlike the former, where the differences were dominated by 
nucleic acids, proteins and lipids, here the differences were mainly in lipids15. Using one 
synchronous cell cycle and analysing fibroblast cells with FTIR spectroscopy in two hour 
intervals, one study found that there were differences in the lipid, and nucleic acid profiles at 
the different time intervals16. The aforementioned studies combine G2 and M phases of the cell 
cycle in the analysis, which was also the approach in this study. This is due to the fact that, in 
flow cytometry analysis, which uses DNA fluorescent markers, the phases that can be 
distinguished are G0/G1 which make up a Gaussian peak with 1x the DNA content, G2M with 
a Gaussian peak of 2x the DNA content and S phase which the population in between G0/G1 
and G2M. 
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The aim of the present study was to investigate the Raman profiles of oral squamous cell 
carcinoma cells at defined phases of the cell cycle and to correlate these with cyclin D1 and 
PCNA expression in the cells at the different cell cycle phases as assessed by flow cytometry. 
In order to assess whether label free Raman signatures can be correlated with established 
biomarkers.   
 
3.2  Materials and Methods 
 
3.2.1  Cell culture 
SCC-4 cells (ATCC, Manassas, VA), a human tongue squamous cell carcinoma cell line, were 
cultured in DMEM F-12 media (Sigma-Aldrich) supplemented with 10% (v/v) foetal bovine 
serum (FBS) (Sigma-Aldrich), 1% (v/v) Penicillin/streptomycin and 400 ng/ml hydrocortisone 
(Sigma-Aldrich). They were incubated at 37°C with 5% CO2 and regularly passaged at 80% 
confluency to maintain exponential growth. The passage number for the experiments did not 
exceed 17. Studies have shown that cells transform at high passage numbers (~40) and show 
altered expression of mRNAs involved in regulated secretion adhesion and proliferation. 
 
 
3.2.2  Cell Synchronisation 
A double thymidine block, described previously17, which arrests cells in the S phase of the cell 
cycle, was used to synchronise the cells. Excess thymidine inhibits DNA synthesis, thereby 
arresting cells in G1, prior to DNA replication, or in S phase. A double thymidine block ensures 
that any cells that were in mid or late S phase during the first block will be captured in late G1 
or early S phase in the second block. SCC-4 cells were cultured in T-125 flasks, they were 
trypsinised at 30% confluency, harvested and counted. The confluency/density of cells affects 
their proliferation rate which can slow down at confluency above 50%18. Cells were counted 
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using a coulter counter, 500,000 cells were seeded into a T-25 flask with 5 ml medium. 
Thymidine was added to the flasks to a concentration of 2 mM and incubated with the cells for 
18 hours.  The cells were then washed with PBS and fresh media was added to release them 
from the Thymidne block, they were then incubated for 9 hours. 2mM Thymidine was then 
added to the flasks for a second thymidine block and the cells were incubated for 17 hours.  
The selected time points were; at time of release from thymidine (0 hours), 6 hours after release, 
and 12 hours after thymidine release. The controls were unsynchronised cells (not treated with 
thymidine), unstained cells (no primary or secondary antibody), negative control cells (no 
primary antibody) and cells with no PI. All time points and controls were completed in 
triplicate. Experiments were performed for detecting both cyclin D1 and PCNA. 
 
M 
G1 G2 
S 
6 hours 
6 hours 
6 hours 
Thymidine 
block 
12 hour 
time point 
0 hour time 
point 
6 hour 
time point 
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Figure 3.1 A schematic of the SCC4 cell cycle. SCC4 cells have an 18 hour cycle (doubling 
time) and spend 6 hours in each of the phases (G1, S, and G2M). The thymidine block arrests 
the cells at the G1/S boundary so when cells are released they enter S phase.  
3.2.3  Flow Cytometry 
Cells were harvested by trypsinisation, washed with PBS, then resuspended in ice cold 
methanol and stored at 4°C overnight. The fixed cells were pelleted and the pellet was dried to 
remove the methanol. The cells were then permeabilised with 0.2% Triton X-100 (BDH) in 
PBS (v/v), washed with PBS, then treated with a primary antibody; for cyclin D1, monoclonal 
rabbit antihuman cyclin D1 antibody (Dako) (1:50 dilution in PBS) and for PCNA, a mouse 
monoclonal [PC10] to PCNA (abcam) (1:50 dilution in PBS). After another PBS wash, for 
cyclin D1 detection,  an anti-rabbit IgG Fluorescein isothiocyanate (FITC) conjugated antibody 
(Sigma-Aldrich) (1:100 dilution in PBS)  was incubated with the cells and for PCNA detection 
a goat Anti-mouse IgG Alexa Fluor conjugated antibody (abcam) (1:100 dilution in PBS)   was 
used. Subsequently, the cells were re-suspended in 0.5 ml of   PI-RNase (BD Biosciences) and 
analysed with a BD Accuri C6 flow cyctometer. The threshold was set at 10,000 events and, 
using forward and side scatter characteristics, gates were set to exclude cell debris. The controls 
were used to determine the quadrants by determining positive signal from background 
fluoresence so the threshold for positivity could be set accordingly. PI and FITC/Alexa Flour 
were plotted in the y and x axis respectively so that cells in the lower left quadrant were 
negative for both and those in the upper right quadrant were positive for both. Cell cycle phase 
was determined by DNA content; PI intercalates with DNA and facilitates DNA quantity 
measurement in the 560-590 nm range of the spectrum using a 585/15 nm optical filter. An 
excitation wavelength of 488 nm was used and Cyclin D1 and PCNA expression was detected 
with a 533/30 nm optical filter.  
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3.2.4  Raman Spectroscopy 
125,000 cells were seeded onto calcium fluoride (CaF2) discs (Crystan, UK) for Raman 
spectroscopy, treated with thymidine and fixed at the previously described time points. The 
cells were fixed with 4% formalin, washed with PBS, then stored in 0.9% physiological saline 
at 4°C. A Horiba Jobin Yvon LabRAM HR 800 Dual Microscope Raman Spectroscope with a 
785nm laser was used to capture the cell spectra. The LabRAM system is a confocal Raman 
spectrometer with a motorised XY sample stage and interchangeable gratings of which the 300 
grooves/mm grating was used, giving a dispersion of ~1.5cm-1 per pixel. The confocal pin hole 
of the system was set to 100μm and a 16 bit dynamic range charge coupled device (CCD) 
detector was used which is Peltier cooled to reduce thermal noise. A 60X /0.9W immersion 
objective (LumplanF1 Olympus, Japan) was used to focus on the samples and collect the 
backscattered light. Point spectra were taken from the nuclei of the cells. The spectral 
acquisition time was 40 seconds per point over two accumulations, and the range over which 
the Raman scattered light was detected was 400-1800 cm-1. 74 spectra, one per cell, were 
collected overall for each time point from two independent experiments.   
 
Data Analysis 
All data analysis was carried out using Matlab (Mathworks, US), with the PLS-Toolbox 
(Eigenvector Research Inc.) and in-house algorithms. 
Spectral Pre-Processing 
The raw Raman spectra were first smoothed using a Savitzky-Golay filter (13 points, 5th order). 
Savitzky-Golay filter increases the signal to noise ratio without distorting the signal. The 
baseline was then corrected using the rubberband method19, and finally the spectra were vector 
normalised (to reduce any variability caused by the fluctuation of excitation power)19. 
Principal component analysis (PCA) 
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 PCA is a form of unsupervised multivariate analysis, which has become a standard processing 
technique for Raman Spectral data20. PCA explains the variance in the data by finding 
combinations of the original dimensions that describe the largest variance between the data 
sets. The output is in the form of a complementary set of score and loading plots termed 
principal components (PCs) 20,21.  
Linear discriminant analysis (LDA) and Classification Model 
LDA is a supervised form of multivariate analysis based on discriminant functions (LDs) which 
maximize the variance between groups and minimize the variance within groups. PCA is first 
used to reduce the data into PCs which are then used to build an LDA classification model with 
leave one out cross validation (LOOCV). In LOOCV all the spectra except for one are used as 
a training set and a prediction is made for the left out spectrum. This is repeated so that each 
spectrum is left out and predicted once22.  
 
3.3  Results 
3.3.1  Cell Cycle Analysis 
DNA content was determined by flow cytometry and related to cell cycle phase as shown in 
Figure 3.2 (representative measurement), and tabulated in Table 3-1 (average of 6 
measurements). At the time of thymidine release, most of the cells were arrested in S phase, 6 
h after release, the majority of the cells were in the G2M phase, while 12 h after release most 
of the cells were in the G1 phase of the cell cycle.  
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Figure 3.2 A representative plot showing cell cycle profile SCC-4 cells; (A) at time of 
thymidine release, (B) 6 hours after thymidine release, and (C) 12 hours after release 
respectively.  
 
Table 3-1 Mean and standard deviation of cell cycle phases at each time point 
 Flow cytometry classification (%) 
 
Time point (h) after 
thymidine release 
S G2M G1 
0 75±5 12±8 9±3 
6 24±12 67±7 9±4 
12 9±3 22±1 62±4 
 
3.3.2  Biomarker expression 
Cyclin D1 expression was assessed by FITC staining, and 3 measurements were made for each 
time point. As can be seen in Figure 3.3, Cyclin D1 expression varied according to the time 
point after release, and therefore cell cycle phase, the highest expression being observed in 
G2M, followed by G1 and the lowest expression being in the S phase. The expression of PCNA 
was assessed by an Alexa Fluor conjugated secondary antibody with 3 measurements made for 
each time point. From Figure 3.4 it appears that PCNA expression is very high in S phase 
(B) (A) 
(C) 
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(~90%) which is reduced to (~60%) in G2M phase and is at its lowest (~10%) in G1 phase of 
the cell cycle. Using one way ANOVA, which determines if three independent groups have 
significantly different means, PCNA expression was found to be significantly variable across 
the different groups (time points). That was not the case with cyclin D1 which was not found 
to have variance across the groups. However a two tailed t test revealed that S phase expression 
is significantly lower than G2M.  
 
Figure 3.3 Cyclin D1 expression at the different time points, related to cell cycle phases. 
Expression is highest at G2M, followed by G1 phase and lowest at the S phase.  A two tailed t 
test showed that S phase expression is significantly (P<0.002) lower than G2M but not G1.  
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Figure 3.4 PCNA expression at different time points, related to cell cycle phases. PCNA 
expression is highest in S phase, followed by G2M and lowest in G1. One way ANOVA test 
showed that PCNA expression is significantly different (P=0.0006) between the different time 
points. 
3.3.3  Raman Spectroscopy 
From their mean Raman spectra (Figure 3.5); differences between the release time points, 
representing the cell cycle phases, were observed. Spectral peak assignments23,24 are tabulated 
in Table 3-2. The nucleic acid (600-800 cm-1) and amide 1 regions (1600-1800 cm-1) are more 
prominent in the G2M phase, the S phase has more prominent protein and lipid features (around 
1400 cm-1), while the G1 phase falls between the S and the G2M phases.  
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Table 3-2 Peak assignments of the main Raman vibrational modes found in the spectra and 
PC loadings23,24 
Wavenumbers (cm-1) Assignments 
621 C-C twist in phenylalanine 
783 DNA/RNA ring breathing 
1004 Phenylalanine ring breathing 
1092 DNA/RNA O-P-O stretching 
1336 DNA bases 
1440 Fatty acids 
1451 Protein (C-H) bending 
1575 DNA/RNA ring mode 
1673 Amide 1 β pleated sheet 
 
PCA was performed, pairwise, on the processed Raman spectra, which revealed a distinct 
separation between the S phase and G1 and G2M phases according to PC1, which explains 
47% and 45% of the variance respectively (Figure 3.6). Figure 3.7(A) shows the loading of 
PC1 for both S vs G1 and S vs G2M. Scores that are on the positive side of a PC in the scatter 
plot reflect the positive side of the loading plot. Similarly, the negative side of the scatter plot 
is represented by the negative side of the loading plot25. For both cases, the loading is 
remarkably similar, although there are some differences. The loadings indicate that the S phase 
is higher in protein content (1451 cm-1, protein C-H bending and 1673 cm-1, Amide 1 vibration) 
than G1 and G2M and there is variability in all 3 at 783 cm-1. PC2 does not discriminate 
between the S and G phases, but does, at least partially, discriminate the G1 and G2M phases, 
for which it explains 8% of the variance. The PC2 loading (Figure 3.7 (B)) shows distinct 
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nucleic acid bands on the positive side (783cm-1, 1092 cm-1, 1336 cm-1 and 1576 cm-1), 
indicative of higher nucleic acid content in the G2M compared to the G1 phase. The band at 
1440 cm-1, on the negative side of PC2, suggests an accumulation of lipids in the G1 phase of 
the cell cycle.  
 
 
Figure 3.5 Mean Raman spectra from SCC-4 cells in each cell cycle phase G1, S, and G2M. 
The shading represents the standard deviation. 
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Figure 3.6 Two dimensional scatter plots of the first two principal components after PCA was 
performed on the spectra from fixed cell nuclei, showing (A) G1 vs S phase (B) S vs G2M and 
(C) G1 vs G2M. S phase separated from the other two phases according to PC1, while G1 and 
G2M phase separate according to PC2. 
(A) (B) 
(C) 
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Figure 3.7 (A) Loading of PC1 in G2M vs S phase PCA (black) and G1 vs S phase PCA (blue). 
S phase is positive in both (B) Loading of PC2 in G2M vs G1 phase PCA. G2M is positive 
(B) 
(A) 
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3.3.4  Classification Model 
To enhance the classification, PCA-LDA with leave one out cross validation was performed 
on the spectra. The resulting confusion matrix, shown in Table 3-3, correctly classified 71 out 
of 74 spectra (96%) at the 0 hour time point, which is consistent with the predominance of the 
S phase, 58 of 74 (78%) at the 6 hour time point, consistent with the predominance of the G2M 
phase and 46 out of 74 (62%) spectra at the 12 hour time point, which corresponds to the G1 
phase. Corroborating the flow cytometry data (Error! Reference source not found.), the p
ercentage of cells correctly classified in each phase from S through G2M then G1 decreases 
corresponding to decreasing synchronicity. Plotting the linear discriminants (Error! R
eference source not found.), a monotonic progression of LD1<LD3<LD2 is apparent in the 
negative peaks at 780 cm-1, 1092 cm-1 and 1339 cm-1, all nucleic acid related. The spectral 
profile is remarkably similar to PC2 which discriminates the G1 and G2M phases in Error! R
eference source not found. (B). LD1 discriminates between G2M and S phase, LD2 
discriminates between G1 and G2M phase and LD3 discriminates G1 and S phase, and the 
similarity of the discriminants indicates that nucleic acid content is the primary biochemical 
difference between the cell cycle phases. 
 
Table 3-3 A confusion matrix utilising LDA with leave one out cross validation of the principal 
component scores showing the Raman predicted percentage of cells at each phase of the cell 
cycle. 
 
 Raman Classification (%) 
Cell Cycle Stage S G2M G1 
S 96 0 4 
G2M 0 78 22 
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G1 7 31 62 
 
Figure 3.8 Linear Discriminants, LD1 discriminates between G2M and S phase, LD2 
discriminates between G1 and G2M phase and LD3 discriminates G1 and S phase. 
Spectra of cyclin D1 and PCNA proteins on CaF2 slides were recorded by Raman spectroscopy 
(Error! Reference source not found.) to determine whether their varying levels at the d
ifferent stages of the cell cycle could be reflected in the PC and LD loadings. The characteristic 
peaks at 812 and 1557 cm-1 of cyclin D1 and at 851 and 1446 cm-1 of PCNA were not, however, 
distinct/apparent in either the PC or LD loadings. 
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Figure 3.9 (A) Spectrum of cyclin D1 (B) Spectrum of PCNA 
 
 
(A) 
(B) 
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3.4  Discussion 
The Raman data showed a good separation between S phase and G1 and G2M phases using 
PCA. Furthermore, the LDA model showed that the classification was highest at S phase 
followed by G2M and G1 phase. This is consistent with the flow cytometry results which 
indicated that the cells were well synchronised at the time of arrest (75% S phase), while the 
synchronicity was reduced in the G2M (67%) and G1 (61%) phases. An important finding was 
that the Raman classification at each phase was higher than its flow cytometry counterpart. 
This may be due to the fact that flow cytometry classification is dependent on just the nucleic 
acid content, while Raman classification takes into account all the biological molecules within 
the nucleus. 
Previous cell cycle studies using Raman spectroscopy have used several methods to 
synchronise the cells at various phases. Matthews et al. used thymidine to synchronise the cells 
at the start of the S phase and nocodazole for synchronisation at the G2/M boundary14, while 
Swain et al. used serum starvation to arrest the cells in the G0/G1 boundary, aphidicolin to 
synchronise the cells in S phase and nocodazole to synchronise them at the G2/M boundary15. 
In this study it was decided to use one cell cycle synchronisation method as opposed to several. 
Although this results in less synchronisation in the latter stages, it eliminates any possible 
differences due to synchronisation method that can influence the analysis, notably the chemical 
signature profiles in the Raman spectra. The differences between G1 and G2M phase were 
mainly due to higher lipid (1440cm-1) content in the former and higher nucleic acids (783cm-1, 
1092 cm-1, 1336 cm-1 1576 cm-1) in the latter, which is consistent with previous findings that 
showed more lipid (700 cm-1, 1438 cm-1) in G1 phase and nucleic acids (669cm-1, 784cm-1, 
1100cm-1, 1340cm-1, 1577 cm-1) in G2M phase14. It is important to note that flow cytometry 
preparations involve a cell permeabilisation step which could lead to alterations in 
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phospholipids. The linear discriminants show a similar progression whereby the nucleic acid 
related peaks (780 cm-1, 1092 cm-1 and 1339 cm-1) are highest in G2M followed by G1 phase 
and lowest in S phase. This is expected, as the DNA condenses in the G2M phase in preparation 
for cell division. The main differences between the S phase and the other two phases, G1 and 
G2M, were in the protein content (1451cm-1, 1672cm-1). This may be due to the fact that the 
expression of many proteins changes throughout the cell cycle so that the differences could 
relate to the changes in specific proteins as opposed to global protein change. 
The Raman spectral profiles in the different cell cycle phases show little evidence of 
contributions of the biomarkers Cyclin D1 and PCNA. Cyclin D1 levels are moderately higher 
in G2M and G1, compared to S phase of the cell cycle. This pattern of cyclin D1 expression 
has been reported previously, yet its cause is not well understood26-28. An explanation could be 
that cyclin D1 levels are lowest in S phase as the result of proteasomal degradation following 
phosphorylation of Thr-286, which occurs specifically in S phase28. On the other hand, PCNA 
is synthesised in late G1 and reaches its maximum in S phase9,29. The localization of PCNA 
within the nucleus reportedly changes throughout the cell cycle. While its equally distributed 
in the nucleus in the G1 and G2 phases, in S phase it aggregates into foci at sites of replication30.  
A previous study has shown a Raman signature of PCNA with similar peaks at 483, 675, 849, 
922 and 1466 cm-1 31. While no previous studies have examined the Raman spectrum of cyclin 
D1, a study by Kumar et al., showing oral tissue with different degrees of cyclin D1 and relating 
it back to Raman spectroscopy using a range of 1200-1800 cm-1 found that the tissues with 
higher cyclin D1 expression had prominent peaks at 1454 cm-1 and 1560-1583 cm-1 consistent 
with the cyclin D1 Raman spectrum measured in his study32.  Cyclin D1 and PCNA are proteins 
with no specific distinguishing moieties which might give them a distinctive Raman signature, 
compared to other proteins. Thus, it is concluded that, in the absence of more refined data-
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mining algorithms, they cannot be used as specific spectroscopic markers for deregulation of 
the cell cycle. 
In summary this study found that Raman spectroscopy can be used to identify the different 
phases of the cell cycle and is perhaps only limited by the efficacy of the cell cycle block. 
Furthermore, data on lipid, protein and nucleic acid profiles of the cells can be generated as 
opposed to other methods which are limited in the information they provide. However, changes 
in particular biomarkers could not be demonstrated with Raman spectroscopy, perhaps due to 
the fact that hundreds of proteins are up or down regulated at different points in the cell cycle 
which makes it difficult to assess particular ones with an unlabelled method. 
The major differences between the phases in the cell cycle are due to variations in nucleic acid 
and protein content of the cells, which are similar to the differences between the degrees of 
dysplasia. Hence, its ability to discriminate the different phases of the cell cycle gives an 
indication of the precision of Raman Spectroscopy in identifying biomolecular changes in the 
SCC4 cells which can later be translated to oral tissue samples to identify differences between 
pathologies. In the next chapter the protocols for pre-processing Raman spectra of oral FFPP 
tissue sections are discussed.   
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Chapter 4: Improved protocols for pre-processing Raman spectra 
of formalin fixed paraffin preserved tissue sections 
Adapted from ‘Ibrahim O, Maguire A, Meade AD, Flint S, Toner M, Byrne HJ, Lyng FM. 
Improved protocols for pre-processing Raman spectra of formalin fixed paraffin preserved 
tissue sections. Analytical Methods 2017;9:4709-4717’ 
OI contribution; experimentation, data analysis and write up. 
 
4.1  Abstract 
Although formalin fixed paraffin preserved (FFPP) tissues are a major resource for 
retrospective studies of disease progression, their use in vibrational spectroscopy studies has 
been undermined by issues of contributions of substrate and paraffin wax which persist in the 
spectra and can compromise spectral analysis. Recognising the microcrystalline nature of the 
wax in the tissue, which are inhomogeneously oriented with respect to the polarisation of the 
Raman source laser, in this study, we have developed a novel method for removing the paraffin 
wax contributions to the spectra using matrices of multiple wax spectra.  FFPP tissue sections 
from the oral mucosca were obtained and, with no further chemical processing, the Raman 
spectral analysis of two regions, epithelium and connective tissue were compared. Matrices of 
multiple wax spectra were collected from different regions and subtracted from the epithelial 
and connective tissue spectra using a least squares analysis with non-negative constraints. 
Spectra of multiple cell components such as DNA and RNA were used in fitting the least 
squares model to reduce the residual error. The use of a data matrix of multiple wax spectra, as 
opposed to a single spectrum, results in a more accurate removal of the wax, hence reducing 
its contribution to spectral analysis. In unprocessed FFPP tissue sections, the contribution of 
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the glass substrate is seen to be minimised in comparison to chemically dewaxed FFPP tissue 
sections. Contributions of the glass substrate were also successfully removed digitally using 
the same methodology. The combined results indicate that direct analysis of FFPP tissue 
sections is feasible using Raman spectroscopy, avoiding the need for chemical dewaxing. 
Additionally, the ability to use glass slides is very important in translation to the clinic. 
4.2  Introduction 
The standard method used in histopathological tissue processing is formalin fixation followed 
by paraffin wax embedding. The tissue is first dehydrated through different grades of ethanol, 
then infiltrated with paraffin wax. In this way, the samples are stabilized and can be stored for 
years. These formalin fixed paraffin preserved (FFPP) archival tissue libraries can potentially 
be a vast resource for retrospective studies of patient history and disease progression. 
Vibrational spectroscopy, including Raman scattering and infra-red absorption, has emerged 
as a promising candidate for rapid, label free automated screening of tissue pathologies, and 
the term spectral histopathology has been coined1. However, paraffin wax poses a difficulty in 
vibrational spectroscopic studies of biological tissues, as the wax peaks are prominent and tend 
to interfere with either FTIR or Raman spectroscopic analysis2,3. A number of different 
approaches to remove the paraffin wax have been tested. Chemical dewaxing agents such as 
xylene, hexane, and histoclear were found to reduce but not completely eliminate the presence 
of wax and the reduction was seen to be proportional to the time the tissue remained in the 
dewaxing agent, resulting in long (up to 18 hours) processing times for optimised protocols3. 
The amount of residual wax was also found to be influenced by the choice of substrate and 
tissue type. Abnormal tissue, such as metastatic tissue, was found to retain more wax after 
dewaxing than normal tissue, while calcium fluoride substrates were seen to retain more wax 
than low E slides4. Another disadvantage of chemical dewaxing is that chemical dewaxing 
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agents have been shown to modify the tissue composition and therefore spectra5,6. The process 
of formalin fixation gives rise to formalin peaks appearing in the spectra at 1041 cm-1 and 1492 
cm-1 which can be removed by washing in PBS7. As the molecular structure of paraffin wax is 
very similar to that of tissue lipids, the Raman spectral profile of the wax overlaps significantly 
with that of the tissue lipids, especially in the region 1000 cm-1 to 1700 cm-1. Because of the 
structural similarities, the process of dewaxing can result in modification of the tissue lipidic 
content6. Digital wax removal methods such as independent component analysis and non-
negatively constrained least squares analysis (NNLS) have been shown to be a promising 
alternative approach. However, these methods tend to introduce artefacts in the spectra due to 
over or underestimation of the wax contribution8,9.  
Another consideration in the spectral analysis of biological tissue is substrate choice. As the 
Raman spectrum of biological samples can be influenced by the optical properties of the 
substrate10. For research purposes, spectroscopists prefer to use spectrally neutral substrates 
such as calcium fluoride or magnesium fluoride, as they contribute a much lower background 
signal compared to glass11. However, they are significantly more expensive and therefore not 
a feasible option for routine diagnostic use11,12. Glass is commonly used in histopathological 
diagnosis as it is the clinical standard, is inexpensive and allows the processing of hundreds of 
samples a day. Its use in Raman spectroscopy, however, is hampered by the fact that glass 
exhibits a strong fluorescence emission under 785nm excitation11 , overlaps with the biological 
spectra in the fingerprint region12 and its contribution was found to vary with cellular 
morphology13. Notably, the glass contribution is significantly lower at 532nm than at the 
commonly employed 785nm, making it the wavelength of choice for such clinically oriented 
studies. Additionally, a shorter wavelength means greater confocality, higher intensity and a 
higher scattering efficacy11. A number of different methodologies have been proposed for 
removal of the glass contribution, including iterative subtraction of a polynomial14 or glass 
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reference spectrum12 and Kerr et al. have recently performed a comparison of EMCS based 
techniques15 to such iterative techniques, suggesting that the former are more effective13.  
The aim of this study was to explore improved methodologies of digitally removing the wax 
contributions to Raman spectra, for the example of oral tissue sections, thereby retaining the 
clinically established tissue processing protocols. The improved methodology is based on a 
recognition that the wax in the tissue has a microcrystalline structure. While this is not a 
significant factor for macro- or unpolarised micro-spectroscopy, as commonly the case for 
FTIR, in the case of Raman microspectroscopy, the microcrystalline domains are randomly 
oriented with respect to the polarisation of the source laser and so contribute inhomogeneously 
to the response, depending on the sampled spot. This inhomogeneity is accounted for by a 
matrix of multiple wax spectra used to digitally process the spectra. The same methodology 
was applied to removal of the glass substrate contributions, illustrating that spectroscopic 
differentiation of tissue regions can be achieved using Raman spectroscopy, free from 
confounding factors of wax and substrate contributions.  
4.3  Materials and Methods 
 
4.3.1  Sample preparation  
Following ethical approval from the Research Ethics Committee, St James’ Hospital, Dublin, 
Ireland, informed consent was obtained from 3 patients who had undergone an oral biopsy 
which was diagnosed as benign oral hyperplasia. Tissue blocks from these patients were 
obtained, for use in the study. 10µm parallel sections were cut from the FFPP tissue blocks and 
mounted on glass slides for Raman spectroscopy.  
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For the chemical dewaxing of tissue sections, routine xylene dewaxing was performed, which 
involves sequentially immersing the FFPP tissue sections in two baths of xylene, two of ethanol 
and one bath of industrial methylated spirits for 5,4,3,2 and 1 minute respectively3. Routine 
Hematoxylin and Eosin (H&E) was performed on parallel tissue sections to aid in the 
delineation of the different regions in the tissues16. 82 component spectra were available from 
an-in house library of spectra of pure biological macromolecules. Matrigel which is a 
solubilised basement membrane preparation, was also trialled as a multicomponent reference 
biological spectrum, at it has previously been employed as such in background correction 
procedures for FTIR 17. Cell components were purchased from Sigma Aldrich. The components 
were placed on calcium fluoride disks prior to Raman spectroscopy measurement. All the 
components were measured in powder form except for DNA, RNA, cytochrome C, stearic acid, 
and collagen which were measured in an aqueous solution. The spectra of the 20 components 
(listed in table 1) selected by the Data Analysis procedure are presented in Supplementary Fig 
1. For the Matrigel measurements; matrigel (Sigma Aldrich) was placed on a calcium fluoride 
disk prior to Raman recording of a matrix of 300 spectral points. 
 
4.3.2  Instrumentation 
A confocal Horiba Jobin Yvon LabRam HR 800 Raman (upright) spectroscopic microscope 
was used to record the spectra of the tissue and biochemical components. The microscope has 
an automated xyz stage and is coupled to a Peltier cooled CCD detector. A 50mW diode laser 
with 532 nm wavelength was used and the grating was set at 600 grooves/mm, while the 
confocal hole was set at 100µm.  For mapping acquisition, the regions to map were selected 
using a 100X objective (MPLAN N Olympus, Japan), which also collected the backscattered 
light. The spectra were acquired over two accumulations, totalling 20 seconds per spectrum. 
The step size was set at 5µm and the spectral range was 400-1800cm-1. The spectra of the cell 
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components were acquired between 10-30 seconds and over 2-3 accumulations depending on 
the quality of the signal from the specific sample.   
 
4.3.3  Data Analysis 
All the data analysis was carried out using Matlab (Mathworks, US) with the PLS-Toolbox 
(Eigenvector Research Inc.) and in-house algorithms. The spectra were preprocessed by first 
smoothing using a Savitsky Golay filter (5th order, 13 points). They were then rubberbanded 
to correct the baseline and vector normalised18. Principal component analysis (PCA), an 
unsupervised multivariate technique, was used to reduce the dimensionality of the data by 
calculating principal components which describe the greatest variance in the dataset19. PCA 
was employed to demonstrate the spectral differentiation of regions of epithelium and 
connective tissue, and the PC loadings were examined to elucidate the biochemical origin of 
the differentiation, as well as contributions of wax or substrate spectral features. 
Classical least squares (CLS) fitting is a supervised technique used to estimate the weighted 
contributions of a set of input spectra to a sample spectrum. It assumes that any complex 
spectrum is the weighted sum of all the base components that contribute to the spectrum as 
described in Equation 120.    
                  Equation 4-1 
where A represents a sample spectrum, a1, a2 and a3 are component spectra and C1, C2 and 
C3 are the weighting coefficients, or concentrations, applied to each component spectrum in 
the summation. If one then considers the case of Raman spectroscopy in which a large number 
of variables are recorded and not all contributing spectral components are known, then there is 
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an error (residual) associated with the estimation which will equate to the difference between 
the sample spectrum and the sum of the weighted spectra: 
     Equation 4-2 
Where Ej is the error associated with the intensity of the jth term (or jth wavenumber). The 
least squares method aims to minimise the error in fitting the sample spectrum, A. The 
minimum error occurs when the differentiation of the sum of squared errors is equal to zero21. 
Differentiation of Equation 4-2 with respect to each of the coefficients results in a set of 
equations which can be solved using simultaneous equations or matrix mathematics. Non 
negatively constrained least squares analysis (NNLS) is a technique similar to that of CLS. 
NNLS is used to estimate the weighted contributions of a set of input spectra in a sample 
spectrum. However, unlike CLS, NNLS introduces non-negative constraints on the weighting 
co-efficients of the input spectra22. 
For this study, in lieu of using an average spectrum of wax or glass, matrices acquired from 
maps of the wax and glass were used. The wax maps were taken from regions in the samples 
with no tissue, while the glass maps were taken from a clean glass slide. The matrices included 
about 300 spectral points and were processed in a similar fashion to the sample spectra. To 
account for spectral drift from day to day, the wax spectra were interpolated to every quarter 
wavenumber. Interpolated spectra were then shifted in both directions in increments of 0.25cm-
1 to a maximum of +/-1cm-1, and then added to the original matrix of wax. Using an in-house 
Matlab algorithm, whereby the Raman spectra of 82 cell components (details in supplementary 
table 1) were iteratively tested to represent the tissue for NNLS and the combination of 
components associated with the least residual error was selected for use in the wax and glass 
subtraction, as listed in Table 4-1 Cell components (Sigma Aldrich) used as inputs for NNLSTable 
81 
 
4-1. The wax and glass matrices were then subtracted from the original processed spectra. The 
steps are summarised in Figure 4.1 The NNLS procedure weighted the contributions of each in 
an unsupervised fashion. However, the intention was to optimise the wax removal protocol, 
rather than to model the tissue analytically, based on the relative contributions of the specific 
components. Least Squares analysis, either supervised or unsupervised, has previously been 
used in a number of studies as a spectral analysis protocol23,24. CLS was used to determine the 
wax contribution to the first principal component of the unprocessed, chemically processed and 
digitally processed tissue. 
 
Table 4-1 Cell components (Sigma Aldrich) used as inputs for NNLS 
 
Cell Components 
Proteins Lipids Nucleic 
acids 
Nucleic bases Glycosaminoglycans Other 
Actin 
Collagen 
Cytochrome C 
L-Histidine 
L-Serine 
L-Theronine 
Peroxidase 
Ubiquitin 
Apo E2 
Stearic acid 
P-Choline 
P-Ethanolamine 
RNA 
DNA 
 
Thymidine 
Uracil 
Guanine 
Heparin 
Hyauloronic acid 
Taurin 
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Figure 4.1 Summary of the processing steps for the Raman spectra. 
 
4.4  Results 
Figure 4.2 shows a H&E stained FFPP tissue section, highlighting the epithelium and 
connective tissue regions. Raman maps were taken of the epithelium and connective tissue 
regions in the unprocessed FFPP tissues, the mean and standard deviation of which can be seen 
in Fig 3. Initially, PCA was performed on the tissue spectra without removing the glass and 
wax contributions (Figure 4.4 (A)). The first principal component (PC1), which explained 59% 
of the variance, does not differentiate the two tissue types, and is dominated by wax peaks at 
1063, 1134, 1172, 1296, 1419, 1441 and 1464 cm-1 (Figure 4.4 (B)), which account for 38% of 
the loading. The broad streaking of the datasets indicates a significant variability of these 
contributions across both datasets. The second principal component (PC2), according to which 
the epithelium and connective tissue spectra are differentiated, explained 5% of the variance 
(Fig 4 (C)). The datasets are more tightly clustered with respect to PC2 and the loading has 
strong peaks at 815, 857, 875, 920 and 1245 cm-1. These relate to collagen type 1 which, 
together with fibroblast cells, is the main component of the connective tissue25,26. The loading 
of PC2 also contains contributions from wax, but notably, some of them contribute negatively 
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to the loading (1419, 1438 cm-1), while some contribute positively (1136, 1296 cm-1) indicating 
that the spectrum of the wax itself is not uniform across the tissue section. Glass peaks do not 
appear in the first or second principal component (Figure 4.4 (C)) indicating that the glass 
contribution to the spectra is not significant. Thus, the differentiation, using Raman 
microspectroscopy, of the two clearly biochemically distinct regions of tissue is based on their 
wax content, rather than their biochemical composition, which does not bode well for the 
potential to distinguish differing pathologies in the same tissue regions. 
 
 
 
Figure 4.2 Bright field image of H&E stained FFPP tissue showing the epithelium and 
connective tissue regions. 
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Figure 4.3 Mean Raman spectra of epithelium and connective tissue in the unprocessed tissue 
sample. Shading denotes the standard deviation. 
The chemically dewaxed tissue sections were visually different from the unprocessed tissue 
sections, as they appeared whiter, indicating increased scatter which may be due to increased 
porosity as the wax and some of the lipidic content is removed in the dehydration process. 
Raman analysis of the chemically dewaxed tissue sections showed that, although the wax peaks 
at 1063cm-1 1134cm-1, 1172cm-1, 1296cm-1, 1419cm-1, 1441cm-1  and 1464cm-1 were reduced 
in comparison to the unprocessed tissue, they were not eliminated. Furthermore, the glass 
contribution in the chemically processed FFPP tissues was higher compared to the unprocessed 
tissues (Figure 4.5 (A)). Acquiring the spectra for connective tissue was problematic, as many 
of the spectra were saturated. This may be due to the increased scattering of the tissue after 
dewaxing, a phenomenon which can be reduced in a water immersion measurement protocol27. 
The epithelium appears to retain more wax and has a higher glass contribution in comparison 
to the connective tissue (Figure 4.5 (B)). 
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Figure 4.4 (A) PCA scatter plot of unprocessed epithelium and connective tissue shows a clear 
separation on the second principal component with even distribution along the first principal 
component. (B) The first principal component is dominated by wax spectral peaks. (C) The 
second principal component is mainly collagen type 1 associated peaks on the positive side, 
relating to connective tissue, and protein associated peaks on the negative side, relating to 
epithelium. 
(C) 
(B) (A) 
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Figure 4.5 (A) Mean Raman spectra of epithelium in the unprocessed (black) and chemically 
dewaxed (blue) tissue sample and mean Raman spectrum of glass (red). Compared to the 
unprocessed epithelial tissue, the chemically dewaxed tissue has less wax contribution and 
more glass. (B) Mean Raman spectra of epithelium and connective tissue in chemically 
dewaxed FFPP tissue section. Shading denotes the standard deviation. The black arrows 
highlight peaks from wax. The epithelium has more wax and glass contribution than the 
connective tissue. 
PCA of the epithelium and connective tissue showed that the collagen and protein related peaks 
815, 857, 875, 920 and 1245 cm-1 had been promoted to the first principal component which 
explains 75% of the variance (Figure 4.6). However, although the contribution has been 
significantly reduced, there was still 32% wax contribution in the loading of the first PC, which 
positively discriminates the epithelium. Additionally, the two broad peaks of glass can be 
discerned in the loading of the first PC. This is to be expected, as there was a higher contribution 
of wax and glass in the epithelium.   
 
(B) (A) 
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Figure 4.6 (A) PCA scatter plot of chemically dewaxed epithelium and connective tissue shows 
a separation on the first principal component. (B) On the positive side of the first principal 
component, collagen type 1 related peaks (red arrows) can be distinguished. While some wax 
(black arrows) and protein peaks can be distinguished on the negative side. 
The spectral dataset for the FFPP sections, in which the wax contribution was removed digitally 
(using NNLS), were analysed. Wax removal with a single wax spectrum was found to be 
insufficient, as most of the wax peaks were either over or underestimated. PCA of the matrix 
of wax spectra clearly illustrates the variability of the spectral signature of the nominally single 
chemical constituent, as shown in the scatterplot in Figure 4.7 (A). Notably, rather than 
exhibiting a widely scattered cluster centred about zero, the curved distribution is suggestive 
of an interdependence of PC1 (Figure 4.7 (B)) and PC2 (Figure 4.7 (C)), each indicating the 
degree of variability of the wax spectrum on a microscopic level. Although, macroscopically, 
paraffin is an amorphous wax, on the microscopic scale of the Raman laser spot, it presents a 
microcrystalline structure28, and, as the laser is polarised, the registered spectrum is 
significantly variable, depending on the relative orientation of the laser polarisation and the 
microcrystalline structures. A single or averaged spectrum does not represent the specific 
(B) (A) 
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spectral contributions at any point on the tissue, and therefore a subtraction protocol based on 
such results in incomplete removal of the spectral contributions of the paraffin.  
 
 
Figure 4.7 (A) PCA scatter plot of Wax matrix. (B) The first Principal component which 
explains 85% of the variance (C) The second principal component (D) Comparison of digital 
wax removal in epithelial tissue using a matrix of wax vs a single wax spectrum. Note, although 
the NNLS protocol constrains the weightings co-efficients to be non-negative, the component 
spectra can have negative contributions. 
(B) (A) 
(D) (C) 
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Rather than averaging; a matrix of 300 individual spectra retains the intrinsic variability of the 
wax contributions, each of which is individually weighted in NNLS subtraction. The protocol 
resulted in much more efficient wax removal, as shown in Figure 4.7 (D). The resultant spectra 
of epithelium and connective tissue appear more uniform and have reduced wax contribution 
(Figure 4.8). This was also reflected in the PCA of epithelium and connective tissue, as the 
wax contribution to the loading of the first PC, which accounted for 90% of the variance, was 
reduced to 10%. The collagen and protein related peaks at 815 cm-1, 857, 875, 920 and 1245 
cm-1 can be clearly distinguished in the first PC.  Additionally, the spectra were tightly grouped 
according to PC1 in the PCA scatter plot, suggesting reduced variability within the groups and 
greater uniformity (Figure 4.9), although considerable point to point sample variability is 
evident by the spread according to PC2, particularly for the case of the connective tissue. 
 
Figure 4.8 Mean Raman spectra of epithelial and connective tissue after digital wax removal. 
Shading denotes the standard deviation. 
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Figure 4.9 (A) PCA scatter plot of epithelium and connective tissue after digital wax removal 
using the cell components as a model. Epithelium is made up of tightly packed cells whereas 
connective tissue contains collagen fibrils, fibroblasts, blood vessels and oil ducts leading to a 
greater variability in the latter according to PC2 (B) First PC after digital wax removal. Wax 
contribution, black arrows, is reduced. The red arrows refer to 815, 857, 875, 920 and 1245 
cm-1 which are collagen related peaks. 
For the glass removal, NNLS was also used. In a similar fashion to the wax removal, the glass 
contribution was reduced without affecting the integrity of the spectra (Figure 4.10). However, 
in contrast to the case of wax, where the use of a matrix conferred a marked improvement, 
there was no real difference between the use of a glass matrix or single spectrum in glass 
removal, indicating that the glass spectrum is more spatially homogenous (Figure 4.10 (B)). 
This is confirmed by the spectra being equally dispersed around the PC1 and PC2 axes, and 
showing no systematic variability (Figure 4.10 (C)). 
(B) (A) 
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Figure 4.10 (A) Mean Raman spectra of chemically dewaxed epithelial tissue before and after 
digital glass removal. (B) Mean Raman spectra of chemically dewaxed epithelial tissue with 
glass removal using a matrix and a single spectrum. (C) PCA scatter plot of the glass matrix. 
 
4.5  Conclusions 
One of the advantages of using vibrational spectroscopy techniques, such as Raman 
spectroscopy, to analyse biological tissues is that they require minimal sample preparation. In 
this study, chemical dewaxing, which increases the processing time and alters the composition 
of the tissue, has been substituted by an improved protocol for digital dewaxing. The demand 
(B) (A) 
(C) 
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for an improved protocol for spectroscopic analysis of the FFPP tissue sections had been 
previously highlighted29. As demonstrated in Figure 4.4 the contributions from the wax 
significantly influence spectral analysis, which establishes the importance of subtracting it. 
From the results, it is clear that this method of digital removal greatly reduces the spectral 
contribution of wax, as the variance from the wax contribution to the first principal component 
is reduced from 38% and 32% in unprocessed and chemically processed samples respectively 
to 10% in the digitally dewaxed samples. Furthermore, the chemically dewaxed FFPP tissue 
samples had more glass background in the epithelium and more scattering background in the 
connective tissue compared to their unprocessed counterparts. This is most likely due to 
refractive index matching between the wax and glass resulting in reduced scattering of the 
incident light and Raman bands themselves in the unprocessed samples. The superiority of 
digital versus chemical wax removal has also previously been reported in FTIR spectroscopy, 
whereby modified extended multiplicative signal correction (EMSC) was used for the wax 
removal30. Because of the variability between, and within, different types of tissue, while using 
a single mean cellular spectrum as a model or reference, such as has been previously reported 
for EMSC, is effective for cytology samples, it underestimates the complexity of 
histopathological tissue samples which can include epithelium and connective tissue, as well 
as different types of pathology13. Similarly, both EMSC and Independent component analysis 
rely on a definitive model of wax (such as a three source model8) which does not take into 
account the variability of the paraffin wax spectrum, accentuated in Raman spectroscopy due 
the polarisation dependence of commonly employed instruments. The use of multiple spectral 
components for the reference and wax contributions provides flexibility to account for the 
observed point to point variations of both. 
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This study is the first to utilize cell components and a wax matrix in the digital removal 
of wax from FFPP tissue sections. As the wax spectrum is composed of a number of 
peaks, and the ratio between these peaks is variable from one wax spectrum to another; 
using a matrix of wax captures this variability which therefore reduces the residual error 
in the NNLS model and results in improved estimated spectra. Paraffin wax is made up 
of linear hydrocarbon molecules which can form crystallites on a microscopic scale21. 
As these can be randomly oriented with respect to the laser polarisation, their 
contribution to the Raman spectrum of the tissue can be highly spatially variable. 
Polarisation dependent studies are frequently employed to study the orientation of, for 
example, molecules in liquid crystals31  and have been employed to study the 
constituents of bone32. A study conducted, exploiting the polarisation dependence in 
biological tissues, has shown that in probing the deeper layers of the tissues the 
backscattered light has a greater chance of being depolarised by diffusion compared to 
the more superficial layers33. 
In contrast, glass has two broad peaks in the fingerprint region. Almost no difference 
was observed in the subtraction of glass using a single glass spectrum and using a glass 
matrix. However, this may be due to the fact that the glass contribution was not high in 
these samples and more or less uniform across the sample, so the matrix subtraction may 
be more effective in samples which show greater variability. 
The cell components were selected from a pool of 82 components based on their fit of 
the NNLS model and, similar to the wax matrix, they confer a significant improvement 
on the wax subtraction. Choosing whether to use a single, commercially available 
component such as Matrigel or collections of biomolecules as representation of tissue 
constituents can depend on the application and the expected variability of the samples 
under investigation. For the application demonstrated here, the cell components gave 
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superior performance in the removal of wax contributions to the spectra as the residual 
error was reduced from 18% when Matrigel was used in the NNLS correction to 8% 
when the cell components were used. A further improvement in the efficacy of removal 
could potentially be achieved by a more representative choice of cellular constituent 
spectra, targeted at specific tissue types. 
By interpolating the wax spectra to every quarter wavenumber and shifting in both 
directions, the small spectral drifts from day to day calibration were accounted for 
resulting in a more accurate wax removal. 
For a diagnostic technique to be translatable into routine clinical use it has to be 
affordable, and reliable. Effective digital subtraction of glass contribution from spectra 
means that glass could be used for FFPP or cytological samples, making vibrational 
spectroscopy techniques more affordable. The digital subtraction of wax using a matrix, 
decreases the processing time and involves less modification of the samples resulting in 
more reliable results.  
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Chapter 5: Raman spectroscopy for the identification of dysplastic 
changes in FFPP oral tissues (an intra-patient study) 
 
5.1  Introduction 
 
OSCC is commonly preceded by a range of cell and tissue alterations, described in Table 5-2, 
which are similar to the changes seen in carcinoma, but restricted to the surface epithelium. 
These changes, termed dysplasia, have been classified by the World Health Organisation 
(WHO), according to their severity, as1; 
Table 5-1 WHO classification of oral dysplasia 
Degree of dysplasia Features 
Mild dysplasia Architectural (tissue) changes limited to the 
lower third of the epithelium with minimum 
cellular atypia 
Moderate dysplasia Architectural changes extend to the middle 
third of the epithelium with cellular atypia 
Severe dysplasia Architectural changes that cover more than 
two thirds of the epithelium with marked 
cellular atypia 
Carcinoma in situ Architectural changes that extend to the full 
thickness of the epithelium with marked 
cellular atypia. The difference between 
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carcinoma in situ and OSCC is the presence 
of invasion in OSCC. 
 
The WHO classification system is the most widely used, although other classification systems 
have been devised, such as the one by Smith and Pindborg which classifies dysplasia as; none, 
present, or marked2. The oral intraepithelial neoplasia (OIN) System classifies dysplasia as 
none, OIN 1 and 2 which correspond to mild and moderate dysplasia respectively and OIN 3 
which corresponds to severe and/or carcinoma in situ3. 
Table 5-2 Cellular and tissue features of oral epithelial dysplasia4 
Cellular changes Tissue changes 
Increased nuclear/cytoplasmic ratio Loss of polarity of the basal cells 
Increased number and size of nucleoli Drop shaped rete ridges 
Cellular pleomorphism (variations in size and 
shape) 
Disordered maturation from basal to squamous 
cells 
Nuclear pleomorphism Increased cellular density 
Increased number of mitotic figures Basal cell hyperplasia 
Abnormal mitotic figures (abnormal in shape 
or location) 
Dyskeratosis (premature keratinization and 
keratin pearls deep in epithelium) 
Hyperchromatic nuclei Loss of intercellular adherence 
 
100 
 
However, as mentioned in section 1.3.5 , histopathological classification is prone to inter- and 
intra- observer errors and the progression of dysplasia is not a linear process, so the degree of 
dysplasia is not necessarily a predictor for malignant transformation5,6. A previous ex-vivo 
study used Raman spectroscopy to classify oral lesions as normal, benign, premalignant and 
OSCC7. An in-vivo study was able to discriminate between normal, premalignant and 
malignant oral mucosa with an accuracy of 85%8.  Another in-vivo study discriminating 
between premalignant lesions, normal mucosa and the mucosa of habitual tobacco users could 
classify the premalignant lesions with an accuracy of 80% using LOOCV and only 50% using 
an independent test set9. However, none of these studies took into account the presence or 
degree of dysplasia in the premalignant lesions.  
The aim of the current study is to use Raman spectroscopy to discriminate between mild, 
moderate and severe dysplasia in FFPP tissues from biopsies of 4 patients who had undergone 
multiple biopsies over time. Studying the range and progression of dysplasia in the same 
patients reduces the differences due to genetic variability and can help understand the 
progression of the disease. Two methods were trailed for classification purposes, PCA-LDA 
which has been described in section 3.3.5 and partial least squares regression discriminate 
analysis (PLSDA). Data for progression in one patient is shown below.  
5.2  Methodology 
5.2.1  Sample preparation 
Ethical approval from the Research Ethics Committee, St James’ Hospital, Dublin, Ireland, and 
informed consent was obtained from a patient who had undergone multiple oral biopsies. 10µm 
sections were cut from the FFPP biopsies and mounted on glass slides. On the slide, the regions 
with the different pathologies (such as mild or moderate dysplasia) were marked by the 
pathologist. 
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5.2.2  Instrumentation 
A confocal Horiba Jobin Yvon LabRam HR 800 Raman (upright) spectroscopic microscope 
with a 532 nm wavelength laser was used. The properties of the spectroscope and mapping 
details were described in chapter 4, section 4.3.3 . Two maps were taken for each pathology, 
one of epithelium and one of connective tissue. Each consisted of 200 spectral points taken at 
10µm intervals.  
5.2.3  Data Analysis 
All the data analysis was carried out using Matlab (Mathworks, US) with the PLS-Toolbox 
(Eigenvector Research Inc.) and in-house algorithms. Two quality control steps were 
employed. In the first, before processing, spectra with excess scatter/background were 
eliminated by setting a maximum intensity. Processing involved smoothing with a Savitsky 
Golay filter (5th order, 13 points) then correcting the baseline with a rubberband function, and 
finally vector normalisation. The second quality control step involved removing the spectra 
with excess wax and low biological content. This was achieved using k-means clustering which 
is used to partition data into groups such that variation is minimized within groups but 
maximized between groups. Most of the current versions are based on the algorithm developed 
by Hartigan and Wong in 197910. It assigns data points to their closest centre points which are 
updated (changed) with each iteration until optimal convergence is met10. The next step was 
subtracting the wax and glass backgrounds; which was done using the NNLS method described 
in section4.3.3 . Figure 5.1illustrates the spectral preprocessing steps. 
PCA of the data was performed to elucidate whether there is discrimination between the 
different pathologies and the basis for that discrimination. 
PCA-LDA: Information from the first 10 principal components was used to build an LDA 
model with LOOCV.  
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PLSDA: mean centering (dividing all the variables by the mean) was performed on the 
processed spectra before PLSDA modelling. This serves to adjust for the variance between 
large and small unit variables, leaving only the relevant variance (that between the samples) 
for analysis. Partial least squares regression (PLSR) is a generalization of multiple linear 
regression (MLR) in which a set of dependent variables y is regressed against independent 
predictor variables X11. PLSDA is a supervised form of multivariate analysis which works as 
a linear classifier that aims to separate the data into groups using a hyperplane, similar to LDA; 
it aims to maximise the variance between groups and minimise the variance within groups. It 
is based on PLSR. Whereas, in classic PLSR, y is a matrix of continuous variables, in PLSDA 
it is categorical and used to assign the observations into classes. The loadings of the 
discriminate hyperplanes or latent variables (LV)s can be plotted to give more information on 
the source of the variance12. The data was divided into y classes from 1 to 3, corresponding to 
mild, moderate and severe dysplasia. 
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Figure 5.1 Spectral processing steps (A) Raw spectra. (B) Spectra after first quality control 
step, smoothing, baseline correction and normalization. (C) Spectra after k-means grouping; 
the spectra in red have high wax and low biological content while those in blue have higher 
biological content and less wax. (D) Spectra after glass and wax subtraction. 
 
 
 
 
 
(B) (A) 
(D) (C) 
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Table 5-3 Raman peak assignments, adapted from Movasaghi et al.13. 
Wavenumber (cm-1) Assignment 
484-90 Glycogen 
599/600 Nucleotide conformation 
666 G,T (ring breathing modes in DNA bases) 
752 Symmetric breathing mode of tryptophan 
782 DNA 
811/12 RNA O-P-O stretch 
814 C-C stretching (collagen assignment) 
838 Deformative vibrations of amine groups  
855 Ring breathing in tyrosine/C-C stretching in proline 
919 C-C stretch of Proline ring/ glucose lactic acid C-C, proline 
ring (collagen assignment) 
934/935 Protein/C-C backbone (collagen assignment) 
937/8 Proline, hydroxyproline (C-C) skeletal of collagen backbone 
1001/2 Phenylalanine ring breathing 
1030-34 Phenylalanine of collagen 
1128/9 Skeletal C-C stretch in lipids 
1131 Fatty acid 
1237 Amide III 
1245-8 Amide III of collagen 
1265 Amide III 
1278 Proteins including collagen I 
1285 Differences in collagen 
1315-17 Guanine 
1333 Guanine 
1336 Polynucleotide chain (DNA purine bases) 
1368 Guanine TRP protein, porphrin, lipids 
1373 T,A,G (ring breathing modes of the DNA/RNA bases) 
1437 CH2 deformation (lipid) 
1441 Wax 
1449/50 C-H vibration lipids 
1460 CH2/CH3 deformation in Lipids 
1554 Amide II 
1572-78 Guanine adenine 
1650 Amide I 
1652-55 Lipid C=C (lipids) / Amide I 
1666-8 Protein / collagen 
1674 C=C stretch in cholesterol 
1700-50 Amino acids aspartic and glutamic acid 
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5.3  Results 
 
According to their mean spectra, mild, moderate and severe dysplasia appear similar (Figure 
5.2), which is why multivariate methods are employed to better observe the differences. 
 
 
 Figure 5.2 Mean Raman spectra of mild, moderate and severely dysplastic epithelial tissue. 
Shading denotes standard deviation. 
PCA showed a good discrimination between mild and severe dysplasia according to PC1 
(Figure 5.3 (A) (B)). Negative peaks in PC1 relating to the mild dysplasia are attributed to lipid 
(1128) and protein (935, 1652 cm-1, 1462 cm-1) contributions (Figure 5.3 (B)). On the positive 
side of the PC loading, relating to severe dysplasia, the most prominent peaks are attributed to 
nucleic acids (666, 1375 cm-1) and protein (1555, 1709 cm-1). Similar results were obtained in 
discriminating moderate and severe dysplasia (Figure 5.3 (C) (D)). Negative peaks in PC1 at 
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666, 1375 cm-1, 1555, and 1709 cm-1 relate to the severely dysplastic epithelium. Positive peaks 
at 715, 934, 1129, 1296, 1445 and 1655 cm-1 relate to the moderately dysplastic epithelium. 
The peak at 1296 cm-1 is a paraffin wax feature whose variance, although reduced, is not 
eliminated. No discrimination was found between mild and moderate dysplasia in PCA (Figure 
5.3 (E) (F)). This suggests that lipids and proteins are more prominent in the mildly and 
moderately dysplastic tissue, while nucleic acids and proteins are more prominent in the 
severely dysplastic tissue. 
According to their mean spectra, differences between mild / moderate and severe connective 
tissue are observable, especially in the regions 800-1000 cm-1 and 1200-1400 cm-1 (Figure 5.4). 
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Figure 5.3 Results of PCA in epithelium (A) PCA scatter plot of mild vs severe dysplasia (B) 
Loading of PC1 which explains 42% of the variance (C) PCA scatter plot of moderate vs severe 
dysplasia (D) PC1 which explains 42% of the variance (E) PCA scatter plot of mild vs moderate 
dysplasia (F) PC1 which explains 31% of the variance. 
 
(A) (B) 
(C) (D) 
(E) (F) 
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Figure 5.4 Mean Raman spectra of Mild, Moderate and severely dysplastic connective tissue. 
Shading denotes standard deviation. 
 
A good discrimination between mild and severly dysplastic connective tissue was 
demonstrated with PCA (Figure 5.5 (A)). The negative side of PC1, which relates to the mildy 
dysplastic connective tissue, was dominated by collagen related peaks at (814, 856, 939, 1034, 
1243 and 1667 cm-1), while, the positive side, relating to severe dysplasia, was dominated by 
nucleic acid contributions (1314, 1335 and 1365 cm-1) (Figure 5.5 (B)). Similar results were 
found on discriminating moderate and severe dysplasia (Figure 5.5 (C)(D)). PCA showed no 
discrimination between the mild and moderately dysplastic connective tissue. 
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Figure 5.5 Results of PCA in connective tissue (A) PCA scatter plot of mild vs severe dysplasia 
(B) Loading of PC1 which explains 75% of the variance (C) PCA scatter plot of moderate vs 
severe dysplasia (D) PC1 which explains 73% of the variance (E) PCA scatter plot of mild vs 
moderate dysplasia (F) PC1 which explains 41% of the variance.  
(A) (B) 
(C) (D) 
(E) (F) 
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Table 5-4 summarises the sensitivity and specificity values obtained from the PCA-LDA 
classification with LOOCV. For both epithelium and connective tissue, severe dysplasia has 
the highest accuracy of discrimination in Raman followed by mild then moderate dysplasia. 
The discrimination in epithelium is better overall than that in connective tissue.  Table 5-4 
displays the sensitivity and specificity values obtained from the PLSDA classification with 
LOOCV. It follows the same trend as the PCA-LDA classification although the sensitivity and 
specificity values are higher overall. 
 
Table 5-4 Sensitivity and specificity values obtained for the PCA-LDA classification model  
 Epithelium Connective Tissue 
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) 
Severe 100 99 98 98 
Moderate 88 95 63 89 
Mild 92 95 79 82 
 
 
Table 5-5 Sensitivity and specificity values obtained for the PLSDA classification model  
 Epithelium Connective Tissue 
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) 
Severe 100 99 98 98 
Moderate 96 95 78 84 
Mild 97 95 91 71 
 
 
5.4  Discussion 
Discriminating between low grade dysplasia (mild and moderate) and high grade (severe and 
CIS) is important, as it determines both the management course and patient prognosis. High 
grade dysplasia have a higher risk of transformation and thus are treated more radically, while 
low grade dysplasia, depending on location and extent, may just be monitored. In this study, of 
interest are the changes taking place in epithelium and connective tissue during mild, moderate 
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and severe dysplasia, as identified by Raman spectroscopy. The choice to study each part of 
the tissue (epithelium and connective tissue) independently was made in order to better 
understand/identify the changes taking place in each. While it was expected to find 
discrimination between severe, mild and moderate in the epithelium, as the epithelial cells are 
undergoing morphological and biochemical changes, significant differences in connective 
tissue between the pathologies was not expected.   
In the epithelium, the most prominent feature in the severely dysplastic epithelium was an 
increase in the nucleic acid related peak at 1375 cm-1 and a reduction in the peaks at 1128 and 
1462 cm-1, which relate to skeletal C-C stretch and CH2/CH3 deformation in lipids, 
respectively, in comparison to the mild and moderately dysplastic tissue. This has previously 
been reported in relation to OSCC14 and can be explained by the higher replication rate and the 
relative increase in nuclear to cytoplasmic ratio in the more severe dysplasia. The spectral 
profile of the tissues in relation to proteins, however, is more complex, as peaks at 934 and 
1650 cm-1, which relate to protein C-C backbone and Amide I/lipids respectively, were higher 
in the mild and moderately dysplastic epithelium compared to severely dysplastic. Similar 
results were found by Cals et al. when comparing OSCC to surrounding normal squamous 
epithelium, as these peaks were higher in the normal epithelium15. On the other hand, severely 
dysplastic epithelium had higher peaks at 752 cm-1 (tryptophan) and 1555 cm-1 (Amide II). 
This suggests fewer proteins in the α helix conformation16 in severely dysplastic epithelium, 
which may be due to disordered protein structure resulting from weakened bonds or a change 
in the amino acid microenvironment17. Increased Amide II may be due to upregulation of some 
proteins in the dysplastic progression, while increased tryptophan, an important amino acid in 
metabolic activities, has been reported previously in malignant cells17-19.  
The most significant change in connective tissue is in the collagen related bands (Table 5-3), 
which is reduced in the more severely dysplastic tissue. This has previously been described in 
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gastric dysplasia and ascribed to changes in matrix metalloproteinases which cleave collagen20. 
It may also be relative to an increase in cellularity in the severely dysplastic tissue. Mild and 
moderately dysplastic tissue did not show a good discrimination on PCA which is not very 
surprising as the categories are sometimes confused by the pathologists especially in borderline 
cases. More supervised classifiers, in this case LDA, and PLSDA were required to find the 
variance.  
Overall, these results suggest that Raman spectroscopy can identify differences in mild, 
moderate, and severely dysplastic tissue which relate to relative changes in nucleic acid, lipid 
and protein content. By analysing these changes in a single patient, any differences due to 
genetic variability have been reduced. In Figure 5.6 the loading of LV-1 from the PLSDA of 
epithelium in each of the 4 patients (A-D) shows the progression from mild through moderate 
and severe. From the loadings it is apparent that while A and B have similar signatures, C and 
D are different.  
 
Figure 5.6 Loading of LV-1 from the PLSDA model for 4 patients A-D 
(C) (D) 
(B) (A) 
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This suggests that there may be some interpatient variability when it comes to progression from 
mild, through moderate to severe dysplasia. Hence doing an interpatient study, where the 
patients are grouped according to class (pathology) can be more informative, this is presented 
in chapter 6. 
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Chapter 6: Raman spectroscopy for the identification of dysplastic 
and malignant FFPP oral tissues (inter-patient study). 
 
6.1  Introduction 
 
In this study, the work from the previous chapter is expanded on by studying the differences 
between benign, mild, moderate, severely dysplastic and OSCC FFPP tissue in a cohort of 
patients. The archival FFPP patient samples were obtained from St James’ Hospital, Dublin. 
The benign category was made up of benign lesions, such as fibroepithelial polyp, squamous 
papilloma and benign hyperplasia. Fibroepithelial polyps are reactive lesions with an 
underlying aetiology of trauma or irritation. They are characterised by a small growth which 
can occur anywhere in the oral cavity, although they are most commonly found in the gingiva, 
tongue and lip1. Similarly, squamous papillomas are exophytic asymptomatic growths, 
although their pathogenesis is assumed to be viral, as they have been tentatively linked to HPV 
types 6 and 112. Hyperplastic lesions are benign lesions that are keratotic but show no cellular 
atypia. Raman spectroscopic measurements were taken of the tissues and partial least squares 
regression discriminate analysis (PLSDA) was used to classify the tissue samples into classes 
of benign, mild, moderate, severe dysplasia and OSCC. PLSDA was chosen over other 
multivariate techniques, such as PCA-LDA and support vector machine (SVM), for a number 
of reasons. Firstly, the results of chapter 5 revealed that it was better at discriminating between 
mild, moderate and severe oral dysplasia. Furthermore,  unlike LDA, it can analyse data with 
numerous x variables, and it works well with data that is noisy or has highly collinear x 
variables3. A study comparing PCA-LDA and PLSDA models for colorectal cancer diagnosis 
found that PLSDA could discriminate between normal and cancerous tissue with a higher 
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accuracy than PCA-LDA4. PLSDA is not without its limitations, however, as it can tend to 
overfit the model, meaning it can classify training data well but not new data5. This can be 
overcome by using a validation data set or, as in this case where there are a small number of 
samples, by using cross validation. 
6.2  Methodology 
6.2.1  Sample Preparation 
 
Archival oral FFPP tissues for each cohort were obtained following ethical approval from St 
James’ Hospital Ethics Committee and informed written consent from patients. In total, 57 
patients were included, from which 72 pathologies were identified. 17 were benign lesions, 20 
mildly dysplastic, 20 moderately dysplastic, 10 severely dysplastic and 5 invasive SCC. The 
H&E stained sections from the different pathologies were examined by a consultant oral and 
maxillofacial pathologist in St James’ Hospital, who then edited the images to mark the areas 
of pathology (Figure 6.1). The FFPP tissue blocks and corresponding images were then taken 
to the RESC laboratory where10µm sections were cut from the FFPP tissues and mounted on 
glass slides. One of the sections from each sample was dewaxed, stained with haematoxylin 
and eosin, and a parallel unstained section (which was not dewaxed) was used for Raman 
spectroscopy measurement. 
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Figure 6.1 Representative H&E images showing the regions of dysplasia marked by the 
pathologist. 
 
6.2.2  Instrumentation 
 
A confocal Horiba Jobin Yvon LabRam HR 800 Raman (upright) spectroscopic microscope 
with a 532 nm laser was used. The instrument and mapping properties are described in section 
4.3.2. For every pathology section, 200 spectral points were taken from epithelium and the 
same from connective tissue at 10 µm intervals. 
 
  
mod 
mild 
Severe 
dysplasia 
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6.2.3  Data Analysis 
 
All the data analysis was carried out using Matlab (Mathworks, US) with the PLS-Toolbox 
(Eigenvector Research Inc.) and in-house algorithms. The spectral pre-processing steps are 
described in section 5.2.3.  
PLSDA with leave one patient out cross validation (LOPOCV) was used to build the classifier. 
LOPOCV is similar to LOOCV except, in this instance, in place of leaving one spectrum out, 
one patient is left out so that all the spectra of the patient are left out and predicted.  
Receiver operating characteristic (ROC) curves were graphed for each class. ROCs are a plot 
of the true positive rate (sensitivity) against the false positive rate (1-specificity) over a 
continuous range (from 0 to 1) of cut-points of a classifier. Each point on the ROC curve 
represents a sensitivity/specificity pair corresponding to a particular decision threshold. 
Accuracy is measured by the area under the ROC curve (AUC), so that, the closer the curve 
tends to the left and top borders, the more accurate the classifier. Conversely, the closer the 
curve is to the diagonal (baseline), the higher the misclassification rate and the lower the 
accuracy6.The baseline is at 0.5, while a perfect classifier would have an AUC of 1.In general, 
an AUC of 0.5 is considered to have no discrimination, while 0.7 to 0.8 is considered 
acceptable. 0.8 to 0.9 is considered excellent while over 0.9 is considered outstanding7. A 
schematic of an ROC curve is shown in Figure 6.2. 
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Figure 6.2 Schematic of an ROC curve. Sensitivity is plot on the y axis and 1-specificity on the 
x axis. Accuracy is increased as the curve goes towards the left and top borders (increasing the 
AUC) and decreases as the curve goes inwards towards the baseline (decreasing the AUC). 
6.3  Results 
 
6.3.1  Epithelial tissue 
 
The mean spectra of the benign, mild, moderate and malignant epithelial tissues all appear 
similar (Figure 6.3), demonstrating the need for more sophisticated multivariate analytical 
techniques, such as PLSDA, to differentiate the tissue pathologies based on the spectral 
signatures of their differing biochemical constituents.  
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Figure 6.3 Mean Raman spectra of benign, mild, moderate and severely dysplastic epithelial 
tissue. The spectra have been offset for clarity and shading denotes standard deviation. 
The results of the PLSDA classification do not show a very good discrimination across the 
groups (Table 6-1). The estimated ROC curves are based on predicted class for each spectrum. 
Sensitivity is calculated from the fraction of in class spectra while the specificity is calculated 
from the fraction not in class for a given threshold. The cross validated ROC curves follow the 
same method except the class predicted when the spectra are left out during cross validation is 
used. From the ROC curves (Figure 6.4) it appears that the classifier has the highest accuracy 
for SCC (AUC=0.71) and lowest for mildly dysplastic epithelium (AUC=0.46). 
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Table 6-1 Sensitivity and specificity values obtained from PLSDA classification with 
LOPOCV of epithelial tissue.  
  Benign Mild  Moderate  Severe OSCC 
Sensitivity (%) 74 67 39 69 65 
Specificity (%) 49 38 86 57 76 
 
To assess whether it affects the classification, different combinations of the pathologies were 
assessed. Combining the severely dysplastic and SCC group did not have much effect on the 
overall model (Table 6-2). However, combining the mild and moderate groups leads to an 
improved classification in the other groups (benign, severe and SCC), but a low classification 
in the mild/moderate group (Table 6-3). 
Table 6-2 PLSDA classification combining the severe and SCC groups 
  Benign Mild  Moderate  Severe/SCC 
Sensitivity (%) 75 67 39 66 
Specificity (%) 49 38 86 75 
 
Table 6-3 PLSDA classification combining the mild and moderate groups 
  Benign Mild/Moderate Severe SCC 
Sensitivity (%) 77 38 74 71 
Specificity (%) 49 86 52 72 
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Figure 6.4 ROC curves for (A) Benign (B) Mild (C) Moderate (D) Severe and (E) SCC 
epithelial tisssues. The blue line is the estimated and the green the cross validated ROC curve. 
AUC is a measure of the accuracy of the classifier, (C) is the calibrated and (CV) is the 
crossvalidated AUC. The red dot(s) represents the calculated sensitivity and 1-specificty on the 
y and x axis respectively. So for eaxample for (A) sensitivity is 0.74 (CV) and 1-specificity = 
(1-0.49)=0.51. 
(E) 
(C) (D) 
(A) (B) 
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To better elucidate the variability between the different classes, their scores on the first latent 
variable (LV-1) were plotted. This shows a large intra-class spread, the greatest spread being 
observed in the moderate group and the smallest in the SCC (Figure 6.5). 
 
Figure 6.5 A plot of the PLSDA scores according to LV-1 
 
Plotting the means and standard deviations of the scores on LV-1 (Figure 6.6) does not show 
an obvious progression, but it can be assumed from their means that the benign and mild are 
mostly negative for LV-1 while moderate, severe and SCC are mostly positive. 
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Figure 6.6 Mean and standard deviation of PLSDA scores of LV-1 
 
LV-1 (Figure 6.7), which is reponsible for 26.23% of the variance, has positive peaks at 783, 
1371 and 1576 cm-1, which relate to nucleic acids (Table 5-3). Negative peaks are observed at 
934, and 1282 cm-1 (relating to protein/collagen) and the amide 1 band at 1650 cm-1.  
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Figure 6.7 LV-1 of the PLSDA model which included all the classes 
 
 
 Connective tissue 
 
From their mean spectra, (Figure 6.8) the most notable difference between benign, mild, 
moderate, severe and SCC connective tissue appears to be in the regions (800-1000 cm-1) and 
(1200-1400 cm-1), similar to the findings of chapter 5 (Figure 5.5). 
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Figure 6.8 Mean Raman spectra of benign, mild, moderate severely dysplastic and SCC 
connective tissue. The spectra have been offset for clarity and shading denotes standard 
deviation. 
 
The results of the PLSDA classification (Table 6-4) show high sensitivities for benign and SCC 
compared to the dysplasia classes. However, the specificity for benign was low, indicating a 
high false positive rate. The classifier has the best accuracy among the classes for SCC 
according to the ROC curve (Figure 6.9). 
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Table 6-4 Sensitivity and specificity values obtained from PLSDA classification with 
LOPOCV of connective tissue 
  Benign Mild  Moderate  Severe SCC 
Sensitivity (%) 81 67 42 59 88 
Specificity (%) 44 46 61 67 72 
 
Plotting the scores of LV-1 shows the greatest intra-class spread in the mild group and the 
smallest in the SCC (Figure 6.10). Plotting the means and standard deviations of the scores of 
LV-1 (Figure 6.11) shows a progression from benign to SCC on LV-1. The means of the benign 
and mild are negative in LV-1 while those of moderate, severe and SCC are positive.  
Positive peaks of LV-1 can be observed at 1005, 1131, 1218, 1337, 1435 and 1581 cm-1 LV-
1(Figure 6.12). The peaks at 1005 and 1581 cm-1 relate to phenylalanine, while those at 1131, 
1218 and 1435 cm-1 relate to lipids and that at 1337 cm-1 relates to nucleic acids. On the other 
hand, negative peaks can be observed; at 811, 855, 938, 1241, 1453 and 1672 cm-1. The peaks 
at (855, 938 and 1241 cm-1) relate to collagen while 1453 and 1672 relate to lipid contributions. 
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Figure 6.9 ROC curves for (A) Benign (B) Mild (C) Moderate (D) Severe and (E) SCC 
connective tisssues. The blue line is the estimated and the green is the cross validated ROC 
curve. AUC is a measure of the accuracy of the classifier. 
 
 
(E) 
(C) (D) 
(A) (B) 
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Figure 6.10 A plot of the PLSDA scores of LV-1 
 
 
 
Figure 6.11 Mean and standard deviation of PLSDA scores of LV-1 
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Figure 6.12 Loading of LV-1 of the PLSDA model which included all the classes 
 
6.4  Discussion 
 
The use of benign lesions as a control category was for logistical reasons (as it is difficult to 
get archival FFPP samples of patients with normal pathology). Besides, since clinicians do not 
usually biopsy normal looking mucosa, it is important to differentiate dysplasia or cancer from 
benign lesions. It was elected not to use the normal areas of dysplastic or SCC tissues because 
previous studies have shown that the cells at the periphery of a malignant lesion may be subject 
to cancer field effects, meaning that they appear histologically normal but have undergone 
molecular changes8,9. LOOCV can tend to overfit the model and overestimate the accuracy of 
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the classifier. Hence LOPOCV, which is better at evaluating classifier performance on new 
samples, was used. 
Results from the PLSDA show a similar trend to the results of chapter 5, indicating increasing 
nucleic acid contributions and lower protein and lipid contributions as dysplasia progresses in 
the epithelium. According to the ROC curves, the accuracy of the classifier was highest for the 
SCC class (AUC=0.71), intermediate (~0.6 AUC) for the benign, moderate and severe classes, 
and lowest (AUC=0.46) for the mild. This is likely due to the fact that the mild is not a very 
well defined category for the classifier leading it to misclassify with benign and moderate. 
Moreover, the fact that combining the mild and moderate categories improves the classification 
in the other categories reinforces that fact that there is considerable overlap between these 
categories. The moderate group had the lowest sensitivity in the PLSDA classification and the 
greatest spread in LV-1, suggesting a higher variability in this group compared to the others.  
In connective tissue, nucleic acid peaks were more prominent with progressive dysplasia and 
collagen peaks were less prominent. Connective tissue associated with SCC could be classified 
from that associated with dysplasia and benign with a high sensitivity and specificity. This is 
to be expected as, due to epithelial mesenchymal transition10; the boundary between epithelium 
and connective tissue in SCC is often lost as a result of islands of epithelium invading the 
connective tissue11. 
When building a machine learning system or classifier, it is expected to be better than or match 
the current state of the art, which in this case is histopathological diagnosis. The findings of 
this study do not fulfil this standard which may be due to a number of factors. Firstly, the small 
sample size makes it harder to build a representative model12, especially when the differences 
between categories is small, as in this case with different degrees of dysplasia. Secondly, this 
model is based on histopathological diagnosis but, as discussed in sections 1.3.5 and 5.1 ; 
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morphological changes are not necessarily predictive of malignant transformation13. In fact, it 
is now emerging that genetic alterations such as abnormalities in the number of chromosomes 
(aneuploidy), losses at 3p, 9p and 17p and mutations in the P-53 gene can be a more important 
prognostic marker14,15. Finally, factors other than the degree of dysplasia can have an influence 
on the Raman spectrum and hence classification. These factors are investigated in chapter 7.  
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Chapter 7: Influence of patient factors and clinical features on 
Raman classification 
7.1   Introduction 
 
Following on from the work of chapter 6, patient factors and clinical features that may have an 
influence on the classification using Raman spectroscopy are explored. Tobacco smoke 
contains carcinogens and has a well-studied connection with the development of both 
dysplastic1 and malignant2 oral lesions, as has been discussed in detail in section 1.2.3.1 . 
Similarly, alcohol consumption has been associated with the development of both oral 
dysplasia1 and cancer2, as detailed in section 1.2.3.2 . The incidence of oral cancer is higher in 
males than females3,4, which is likely due to habits such as smoking and alcohol consumption 
rather than a genetic predisposition, although the prognosis is the same5. Gender was not found 
to have an association with the development of oral dysplastic lesions1. Further variability can 
arise because of the different sites of anatomical origin of the lesion. Oral cancer refers to any 
cancer in the oral cavity proper which includes; the tongue, labial and buccal mucosa, hard and 
soft palate, gingiva, alveolar ridges and floor of the mouth. These areas vary in degree of 
keratinization, vascularity and lymphatic drainage5 and thus anatomic site may also influence 
the spectroscopic signatures upon which a classification is to be based. As the interpatient study 
was based on a heterogeneous group of patients with different gender, age, habits, medical 
histories and lesion clinical features, the aim of this chapter was to discern whether these factors 
have an influence on the classification using Raman spectroscopy.   
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7.2   Methodology 
 
7.2.1  Sample Preparation 
The archival FFPP tissue samples detailed in section 6.2.1 were used in this study. 
7.2.2  Instrumentation 
Instrument and mapping properties were described in section 4.3.2 . The maps taken for section 
6.2.2 were used in this study.  
7.2.3   Data analysis 
Metadata on the patients included in chapter 6 is provided in Table 7-1. This was used to divide 
all the patients, regardless of histopathological diagnosis, into groups according to gender, 
smoking habits, alcohol consumption and site of lesion. The spectral maps, acquired for the 
study of chapter 6, were analysed using PLSDA with LOPOCV, as described in section 6.2.3  
Table 7-1 Information on patient factors and clinical features 
Patient Gender Age Smoking Alcohol 
Consumption 
Site of Lesion 
1 M 59 No Yes Retromolar area 
2 F 38 n/a n/a Tongue 
3 M 86 No Yes Tongue 
4 F 75 No Yes/rarely Buccal mucosa 
5 M 50 n/a n/a Tongue 
6 F 66 No Yes Hard palate 
7 F 45 N/A n/a Premolar ridge 
8 F 32 Ex-smoker No Tongue 
9 F 59 No Yes/2-3 
units/fortnight 
Buccal mucosa 
10 F 61 Yes 8-10 
cpd/week 
No Hard palate 
11 F 62 15-20 cpd No Soft palate 
12 M 71 Ex-smoker n/a Gingiva 
13 F 62 No Yes/occasionally Labial mucosa 
14 M 21 n/a n/a Tongue 
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15 F 62 Ex-smoker No Floor of the mouth 
16 F 69 Yes 10 cpd Yes Tuberosity 
17 M 67 Ex-smoker Yes Tongue 
18 M 37 Yes No Buccal mucosa 
19 M 57 1-2 cpw 10 units/week Soft palate 
20 F 65 n/a 1-2 units/week Buccal mucosa 
21 M 60 Ex-smoker n/a Hard palate 
22 M 81 Ex-smoker 2-3 units/week Tongue 
23 M 69 30 cpd 4 units/day Floor of the mouth 
24 M 55 No n/a Maxilla 
25 F 77 No 6 units/week Gingiva 
26 F 47 15 cpd 10-12 units/week Tongue 
27 F 63 Ex-smoker 2 units/week Tongue 
28 F 55 n/a n/a Labial mucosa 
29 F 44 No 5-6 units/week Tongue 
30 M 74 n/a n/a  
31 M 68 Ex-smoker 5 units/week Tongue 
32 M 66 n/a n/a Soft palate 
33 M 58 15 cpd 15 units/week Labial mucosa 
34 M 56 20 cpd 5-6 units/week Buccal mucosa 
35 F 53 n/a n/a Buccal mucosa 
36 F 53 15 cpd Yes 3 units/week Floor of the mouth 
37 M 38 Ex-smoker Yes Buccal mucosa 
38 F 63 No n/a Tongue 
40 F 71 No No Tongue 
41 F 61 No Yes Labial mucosa 
42 F 66 Ex-smoker Yes Soft palate 
43 M 54 Yes 30 cpd No Alveolus 
44 F 51 Ex-smoker Yes Buccal mucosa 
45 F 41 n/a Yes 1 unit/week Buccal mucosa 
46 F 73 n/a Yes Tongue 
47 M  n/a n/a Tongue 
48 M 30 Yes 1 cpd Yes 20-30 units/week Tongue 
49 F 61 Ex-smoker Yes Tongue 
50 F 71 No No Buccal mucosa 
51 F 64 Ex-smoker Yes Tongue 
52 M 47 Yes Yes Buccal mucosa 
53 F 76 Ex-smoker Yes Alveolus 
54 M 53 Ex-smoker Yes Labial mucosa 
55 M 31 Yes No Tongue 
56 F 50 Ex-smoker No Tongue 
57 F 56 Ex-smoker No Tongue 
 
n/a, information was not available 
cpd, cigarettes per day 
cpw, cigarettes per week 
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7.3   Results 
 
7.3.1  Gender 
 
The data of all the patients (Table 7-1) was split according to gender into females and males. 
PLSDA results, expressed in terms of ROC curves, of epithelium (AUC =0.43) and connective 
tissue (AUC=0.47) (figure 7.1) show no discrimination based on gender. The female vs male 
sensitivity and specificity values were 22% and 77% respectively in epithelium. In connective 
tissue the sensitivity was 62% and specificity was 44%. 
 
 
 
Figure 7.1 ROC curves for (A) Epithelium and (B) Connective tissue of Female vs Male. The 
blue line is the estimated and the green the cross validated ROC curve. AUC is a measure of 
the accuracy of the classifier, (C) is the calibrated and (CV) is the crossvalidated AUC. 
 
 
 
(A) (B) 
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7.3.2  Smoking  
 
According to smoking status, the patients in table 7-1 were divided into 3 groups; non-smoker, 
ex-smokers (previous smokers) and smokers. 
 
Table 7-2 Sensitivity and specificity values from PLSDA with LOPOCV for smoking status in 
epithelium  
  Non smoker Ex-smoker Smoker 
Sensitivity (%) 83 81 52 
Specificity (%) 46 38 88 
 
The PLSDA results showed high classification sensitivity for Non-smokers and Ex-smokers 
but lower specificities. On the other hand, the classification sensitivity was lower for smokers 
but the specificity was higher (Table 7-2). The ROC curve (Figure 7.2) shows a significant 
accuracy (AUC=0.76) of the classifier for smokers. To further understand the source of the 
variance, non-smoker and ex-smokers were combined and the scores of LV-1 and LV-2 were 
plotted against smokers (Figure 7.3). While there is some overlap, smokers are mainly negative 
in LV-1 while non-smoker/ex-smokers are mainly positive. According to LV-1, negative bands 
at 667, 784, 1372, and 1573 cm-1 suggest higher nucleic acids in the epithelium of smokers. 
Non-smoker/ex-smokers had a more prominent amide I band at 1651 cm-1 and protein band at 
934 cm-1 (Figure 7.4).     
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Figure 7.2 ROC curves for (A) Non-smoker (B) Ex-smokers and (C) Smokers epithelium. The 
blue line is the estimated and the green the cross validated ROC curve. AUC is a measure of 
the accuracy of the classifier, (C) is the calibrated and (CV) is the crossvalidated AUC. 
(A) (B) 
(C) 
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Figure 7.3 Scores of Smokers and Non-smoker/Ex-smokers on the latent variables from the 
PLSDA model. 
 
Figure 7.4 Loading of LV-1 from PLSDA of Smokers vs Non-smoker and Ex-smokers in 
epithelial tissue. 
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In connective tissue, while there is some degree of classification ( 
Table 7-3), according to the ROC curves for non-smoker (AUC=0.43) ex-smokers (AUC=0.51) 
and smokers (AUC=0.64), the accuracy is not significant (Figure 7.2). 
 
Table 7-3 Sensitivity and specificity values from PLSDA with LOPOCV for smoking status in 
connective tissue 
  Non smoker Ex-smoker Smoker 
Sensitivity (%) 70 39 54 
Specificity (%) 39 69 71 
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Figure 7.5 ROC curves for connective tissue of (A) Non-smoker (B) Ex-smokers and (C) 
Smokers. The blue line is the estimated and the green the cross validated ROC curve. AUC is 
a measure of the accuracy of the classifier, (C) is the calibrated and (CV) is the crossvalidated 
AUC. 
 
7.3.3  Alcohol 
Alcohol consumption in the patient group was varied (Table 7-1). For the sake of simplicity, 
as the patient numbers were not large, they were divided into 2 main groups; alcohol consuming 
and non-alcohol consuming. According to this grouping, PLSDA was performed on epithelium 
(AUC=0.57) and connective tissue (AUC=0.63). No significant discrimination was found in 
either based on alcohol consumption (Figure 7.6). 
(A) (B) 
(C) 
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Figure 7.6 ROC curves for (A) Epithelium and (B) Connective tissue of Alcohol consuming vs 
Non-alcohol consuming. The blue line is the estimated and the green the cross validated ROC 
curve. AUC is a measure of the accuracy of the classifier, (C) is the calibrated and (CV) is the 
crossvalidated AUC. 
7.3.4  Anatomical Site of lesion 
The lesions come from different anatomical sites in the oral cavity, as detailed in Table 7-1. 
Raman spectra of lesions from the tongue, buccal mucosa, soft palate, hard palate and labial 
mucosa were assessed using PLSDA with LOPOCV. 
Table 7-4 Sensitivity and specificity values from PLSDA with LOPOCV for oral site in 
epithelium 
  Tongue Buccal 
mucosa 
Soft palate Hard palate Labial 
mucosa 
Sensitivity (%) 81 50 32 40 72 
Specificity (%) 31 83 72 41 27 
 
While the sensitivity values for tongue and labial mucosa were high, 81 and 72% respectively, 
(Table 7-4), the ROC curves (Figure 7.7) were not significant for any of the oral sites (all AUC 
(A) (B) 
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values were less than 0.7). Similarly, in connective tissue the hard palate and the labial and 
buccal mucosa could be classified with a high sensitivity (Table 7-5) but again AUC values 
were not significant (Figure 7.8). Note that, in Figure 7.7(C) (D) and (E), there is a large 
difference between the cross validated and estimated ROCs. This is likely due to the small 
number of patients with lesions in these sites hence when one patients spectra are taken out this 
is equivalent to a quarter of the dataset of that site which results in an unstable model6.  
 
Table 7-5 Sensitivity and specificity values from PLSDA with LOPOCV for oral site in 
connective tissue 
  Tongue Buccal 
mucosa 
Soft palate Hard palate Labial 
mucosa 
Sensitivity (%) 47 75 51 83 87 
Specificity (%) 78 27 25 54 56 
 
 
Grouping according to keratinised (Tongue and hard palate) and non ketatinised (soft palate, 
buccal and labial mucosa) did not show a good discrimination, sensitivity of 33% and 
specificity of 88% in epithelium and 35 and 75% sensitivity and specificity in connective tissue 
respectively. 
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Figure 7.7 ROC curves for (A) Tongue (B) Buccal mucosa (C) Soft palate (D) Hard palate and 
(E) Labial mucosa of epithelial tissue. The blue line is the estimated and the green is the cross 
validated ROC curve. AUC is a measure of the accuracy of the classifier, (C) is the calibrated 
and (CV) is the crossvalidated AUC. 
 
(A) (B) 
(E) 
(C) (D) 
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Figure 7.8 ROC curves for (A) Tongue (B) Buccal mucosa (C) Soft palate (D) Hard palate and 
(E) Labial mucosa of connective tissue. The blue line is the estimated and the green is the cross 
validated ROC curve. AUC is a measure of the accuracy of the classifier, (C) is the calibrated 
and (CV) is the crossvalidated AUC. 
(A) (B) 
(E) 
(C) (D) 
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7.3.5   Presence of inflammation 
 
All the pathologies were evaluated for the presence of inflammation (H&E stained slides were 
evaluated under a bright-field microscope by the investigator). Table 7-6 shows the number of 
inflamed samples per class. PLSDA was used to classify inflamed vs non-inflamed for all the 
pathologies combined. The results show that inflamed tissue can be classified from non-
inflamed tissue with sensitivity and specificity values of 68% and 70%, respectively, in 
epithelium and 77% and 86%, respectively, in connective tissue. The AUCs were significant, 
at 0.72 for epithelium and 0.84 for connective tissue (Figure 7.9).  
 
Table 7-6 Number of inflamed samples per class 
Class Benign 
(n=17) 
Mild 
(n=20) 
Moderate 
(n=20) 
Severe 
(n=10) 
SCC 
(n=5) 
Number 
Inflamed 
2 3 9 7 5 
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Figure 7.9 ROC curves for (A) Epithelium and (B) Connective tissue of Inflamed vs Non-
inflamed in all classes. The blue line is the estimated and the green the cross validated ROC 
curve. AUC is a measure of the accuracy of the classifier, (C) is the calibrated and (CV) is the 
crossvalidated AUC. 
To ensure that the results obtained are due to the presence of inflammation rather than the 
pathology (as most of the severe and SCC samples were inflamed which could skew the 
results), inflamed vs non-inflamed was assessed in the moderate category. The results show a 
very high accuracy in connective tissue (AUC=0.94) and, to a lesser extent, in epithelium 
(AUC=0.69) (Figure 7.10). Plotting the scores of the latent variables shows a good separation 
based on LV-1, the majority of inflamed spectra having negative scores while the majority of 
non-inflamed spectra have positive scores on LV-1 (Figure 7.11). Note, the group of non- 
inflamed that are outside the 95% confidence interval are likely from one patient who was 
misclassified due to increased variability from the rest of the non-inflamed group. The loading 
of LV-1 (Figure 7.12) shows positive peaks at 813, 855, 939, 1031, and 1245 cm-1 which relate 
to collagen (Table 5-3), while the negative peaks relate to nucleic (1334, 1580 cm-1) and fatty 
acids (1132, 1438 cm-1).  
  
 
(A) (B) 
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Figure 7.10 ROC curves for (A) epithelium and (B) connective tissue of inflamed vs non-
inflamed in the moderately dysplastic lesions. The blue line is the estimated and the green the 
cross validated ROC curve. AUC is a measure of the accuracy of the classifier, (C) is the 
calibrated and (CV) is the crossvalidated AUC. 
 
Figure 7.11 Scores obtained from the PLSDA model of inflamed and non-inflamed moderately 
dysplastic connective tissue on the latent variables.  
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Figure 7.12 Loading of LV-1 from the PLSDA model of inflamed vs non-inflamed connective 
tissue  
7.4  Discussion 
The findings of the current study suggest that no clear Raman classification could  be made 
based on gender, alcohol consumption or site of lesion. The link between alcohol consumption 
and carcinogenesis is not well understood, for, while alcohol can act as a synergistic agent for 
other carcinogens, its main metabolite, acetaldehyde, is believed to have a role in DNA 
damage9. Previous studies suggest that the risk of developing oral cancer increases with 
quantity of alcohol intake10. Unfortunately this study was limited in that information on alcohol 
intake quantities was not available for all patients. To date, no studies have looked at the effect 
of alcohol on the oral mucosa using Raman spectroscopy. Previous studies have investigated 
Raman classification of oral mucosal sites. Bergholt et al. found that the sites in normal/healthy 
oral mucosa can be clustered into three groups; (1) buccal, inner lip, and soft palate; (2) dorsal, 
ventral tongue, and floor; (3) gingiva and hard palate7. Sahu et al., studying normal, and 
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malignant oral mucosa found that while the tongue and buccal mucosa could be classified by 
Raman spectroscopy in healthy mucosa with some degree of accuracy, classification could not 
be achieved in malignancy8.  
From the results, it is apparent that some factors other than the degree of dysplasia can influence 
the Raman classification. Smoking status was seen to impact on the classification of epithelial 
tissue (AUC=0.76). This is consistent with previous work by Singh et al., who have shown that 
the oral buccal mucosa of smokers is more likely to misclassify with that of premalignant 
lesions than that of non-smokers11,12. This is likely due to the fact that smoking is an 
aetiological factor in developing oral dysplasia, and hence biochemical changes occurring in 
the mucosa of smokers are similar to those occurring in dysplastic lesions. 
What was found to have a significant influence on the Raman classification, however, was the 
presence of inflammation in connective tissue (AUC=0.94). Reduced collagen features and 
increased nucleic acid features in the Raman spectra of inflamed connective tissue were the 
main findings. The nucleic acid features may be due to increased cellularity caused by the 
inflammatory cells infiltrating the tissue. The reduction of collagen features is likely due to the 
breakdown of collagen by matrix metalloproteinases (especially MMP-8) which are 
upregulated in inflammation13. In this study, most of the severely dysplastic and SCC tissue 
was found to be inflamed, which is consistent with a previous study that has shown increasing 
inflammatory cell infiltration with increasing severity of oral dysplasia and SCC14. The 
presence of inflammation in the tumour microenvironment has been well documented15,16 and 
is due to multiple factors. The environmental factors that prompt carcinogenesis, such as 
alcohol and smoking, have been shown to trigger an inflammatory response17. Furthermore, 
the tumour cells release inflammatory mediators which generate an inflammatory 
microenvironment that promotes cancer growth, invasion and metastasis18. A study looking at 
OSCC surgical margins found that inflamed connective tissue was more likely to misclassify 
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with SCC than non-inflamed connective tissue19. Of note is the fact that the FFPP tissue from 
chapter 5 (Figure 5.5) also showed inflammation which would explain the similar signature in 
connective tissue. 
While it has been reported that age related physiological changes can be discriminated with 
Raman spectroscopy11, most of the patients in this cohort were between 50-60 years, and hence 
there was not enough variation to study age related factors. Other patient factors and clinical 
features which have not been considered, due to lack of metadata, can still have an influence 
on the Raman classification. These include HPV and candida status of the patients, the size of 
the lesions, and the degree of differentiation in the SCC lesions.   
To sum up, these findings suggest that it is important when studying tissue pathologies to 
consider them in the context of patient factors and clinical features which emphasises the need 
for large scale studies with more representative patient samples. 
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Chapter 8: Conclusions and future work 
8.1  Conclusions 
8.1.1  Summary of findings 
The primary objective of this thesis was to evaluate the potential of Raman spectroscopy in 
diagnosing premalignant oral lesions. The first two chapters act as an introduction to the thesis, 
Chapter 1:introducing clinical aspects of OSCC and dysplasia, while Chapter 2: places the 
emphasis on diagnostic techniques. In Chapter 3: the aim was to establish whether Raman 
spectroscopy can differentiate the different phases of the cell cycle in an oral squamous cell 
carcinoma cell line and how that correlates with biomarker expression levels. The findings 
were that Raman spectroscopy could differentiate the different phases of the cell cycle based 
on nucleic acid, protein and lipid content. However it was not possible to correlate the 
expression levels of cyclin D1 and PCNA to the Raman profiles. This may be due to the fact 
that a Raman profile of a cell carries a great deal of information and, as many molecular 
processes take place inside the cell, it is difficult to extract information on one particular 
biomarker. This demonstrates both the strengths and weaknesses of Raman spectroscopy for 
biological samples as it is sensitive in that it can detect small changes in the cell as it moves 
through the cell cycle, but because it is a label free technique, distinguishing information on 
one variable is more difficult. In Chapter 4:the aim was to optimise the FFPP tissue processing 
for Raman spectroscopy. One of the main difficulties in performing Raman spectroscopy on 
FFPP tissues is that the paraffin wax, in which the tissues are embedded, has a very intense 
Raman signal and is hard to remove with the routine chemical dewaxing  techniques which 
change the composition of the tissue. The same is true of glass, which is generally used in 
histopathology laboratories as a substrate for FFPP tissues .To solve the issues with the glass 
and wax background; a novel method was developed whereby cell components were used as 
inputs for NNLS subtraction and glass and wax matrices were digitally subtracted from the 
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spectra. The use of matrices captures the variability in the wax or substrate spectra which 
improves the subtraction. In Chapter 5:, the different levels of dysplasia; mild, moderate and 
severe were assessed in the FFPP tissue sections within the same patients. This was done in 
order to gain insight into the differences between the different levels of dysplasia without 
influence from other patient variables. Using PCA-LDA with LOOCV, it was found that 
Raman spectroscopy could classify the different levels of dysplasia with an accuracy of over 
90% in epithelium and over 76% in connective tissue. In Chapter 6: benign, mild, moderate, 
and severely dysplastic and SCC FFPP tissues were assessed in a cohort of patients using 
Raman spectroscopy. PLSDA with LOPOCV was used for classification. The results showed 
that SCC could be classified from the other pathologies with over 70% accuracy in epithelium 
and connective tissue. However, the accuracy of Raman spectroscopy for differentiating 
between different levels of dysplasia was lower. In Chapter 7: other variables which could have 
an influence on classification based on the Raman spectra were assessed. From the results, it 
was clear that smoking had the greatest influence in epithelium while the presence of 
inflammation had the greatest influence in connective tissue. 
8.1.2  Clinical relevance 
Currently, there is a lot of interest in using Raman spectroscopy as a diagnostic aid. However, 
a number of factors need to be evaluated before it can be translated into clinical use. For ex-
vivo studies, using inexpensive substrates is of paramount importance. The novel method 
developed in Chapter 4: for removing the substrate background has been used for a number of 
varied studies1-4. The method is both reproducible and adaptable, as the pure components can 
be selected based on the constituents of the cells/tissues/fluid under study. Furthermore, the 
method of validation of the classifier is very important in determining how well it can classify 
future (unseen) samples. For the interpatient studies, chapters 6 and 7, it was elected to use 
LOPOCV as, although it has been shown to give lower accuracies than LOOCV5, due to the 
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presence of biochemical differences between patients, it is better at evaluating classifier 
performance on new samples as it avoids overtraining the model. While this study used ex-vivo 
samples, the results can guide the development of the technique for in-vivo use. Having a 
diagnostic aid such as Raman spectroscopy that can be developed for use chairside, would not 
only aid in selecting the region to biopsy in large lesions, but can also reduce the number of 
biopsies needed for monitoring. Important factors to consider in clinical translation include 
instrument properties. The Raman instrument should be; small, easily transportable, 
inexpensive, easily aligned and calibrated, and have an optical probe that is sterilisable6. The 
finding that Raman spectroscopy can differentiate between cancer and dysplasia is very 
important, as the management and prognosis is different for both. Dysplasia is a common 
finding in tumour borders and regenerative changes which mimic dysplasia can often be found 
in the margins of resected tumours7. The balance between being conservative and maintaining 
as much of the tissue as possible, which is important both aesthetically and functionally, and 
removing enough of the tumour to prohibit recurrence is a difficult one in oral cancer surgery. 
Hence the ability of Raman spectroscopy to discriminate between cancerous and dysplastic 
and/or healthy tissue can be important in striking that balance8. 
8.2  Future perspectives 
A more comprehensive study with a larger sample size9 which takes into account inherent 
patient variability in addition to other variables such as age, smoking, alcohol consumption, 
site of lesion, presence of inflammation etc. may result in a better classifier. The use of a larger 
sample size would also allow for an independent validation set which can better evaluate the 
performance of the classifier. The dataset in the current study did not include any dysplastic 
lesions that had transformed into OSCC. However, a study looking at such lesions and 
comparing them with dysplastic lesions that did not progress to OSCC in a given time period, 
for example in a 5 year period, can be more informative, as morphology is not a predictor of 
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malignant transformation. Hence, a study of transformed lesions could be of more value. As 
Raman spectroscopy identifies molecular bonds that are common to many different 
biomolecules as opposed to identifying individual biomolecules, changes with dysplasia/cancer 
are often subtle and spectrally distributed, requiring full spectral scanning10. However, if 
biomolecules are identified that both have an enhanced Raman signal and vary with increasing 
dysplasia they can act as label free spectral markers which could make the Raman classification 
faster and more accurate. Additionally, the Raman spectrum can be open to different 
interpretations as to the source of the peaks. Although previous studies have explored the 
biochemistry behind the various peak assignments there is still no accepted standardised 
database for Raman peak assignments. Finally, it is difficult to compare Raman spectroscopic 
studies of the oral mucosa as the sample collection, spectral processing and data analysis 
techniques differ between laboratories, an international standardisation of protocols would go 
a long way to taking Raman spectroscopy closer to clinical translation. 
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Appendices 
Appendix 1 Cell protocols 
Cell Passaging 
Cells were cultured in sterile vented culture flasks of size (25, 75 or 125cm2) depending on the 
experiment. For passaging; 
1. 3 ml of trypsin/EDTA solution are added to the flask to detach the adherent cells and 
incubated for 3-5 minutes.  
2. Once the cells have detached 7 ml of media are added to stop the trypsin and the cell 
suspension is then transferred onto a sterile universal tube and centrifuged for 5 minutes 
at 1200 rpm.  
3. After centrifugation the supernatant is discarded carefully without disturbing the cell 
pellet. 
4. For a 1:10 split 10 ml of media is added to the cells which are then carefully 
resuspended in the media. 
5. In a new sterile cell culture flask 20 ml of media is added together with 1 ml of the cell 
suspension from step 4. 
Cell Counting 
A Z series Coulter counter (Beckman Coulter Life Sciences) was used for cell counting. To 
count the cells; 
1. Cells are trypsinised and media added as in steps 1-2 of passaging.  
2. 1 ml of the cell suspension is added to 20 ml of Isoton electrolyte solution in a vial 
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3. Following set-up the vial is placed on the stage of the coulter counter and the stage is 
moved up to the probe 
4. To do the cell count press set up then start 
5. A reading is displayed showing the number of cells/ml 
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Appendix 2  
Dewaxing protocol 
1. Place slides in 1st xylene for 5 minutes 
2. Transfer slides to 2nd xylene and leave for 4 minutes 
3. Transfer slides to 1st ethanol and leave for 3 minutes 
4. Transfer slides to 2nd ethanol and leave for 2 minutes 
5. Transfer slides to IMS and leave for 1 minute 
6. Transfer to water for 1 minute 
H&E protocol  
After step 6 of dewaxing; 
1. Add a few drops of haematoxilyn to the tissue section (enough to cover the tissue) and 
leave for 3 minutes 
2. Rinse in running tap water for 5 minutes 
3. Add a few drops of eosin and leave for 3 minutes 
4. Rinse in tap running tap water for 2 minutes 
Rehydrate and clear by passing through; 
5. IMS for 3 minutes 
6. Transfer to 1st ethanol for 3 minutes 
7. Transfer to 2nd ethanol for 3 minutes 
8. Transfer to 1st xylene for 3 minutes 
9. Transfer to 2nd xylene for 3 minutes 
10. Add a few drops of dpx mountant to the cover slip 
11. Carefully place the slide over the cover slip 
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